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9CHAPTER 1
INTRODUCTION
Cardiovascular ultrasound has become the dominant non-invasive imaging technology in
clinical cardiology. Its role has been established for the assessment of cardiovascular function
at diagnosis and follow-up (Figure 1). Several different methods are available for the
functional assessment of cardiac function and vascular elasticity, which includes stress
echocardiography, contrast echocardiography and indirect vascular distensibility
measurements. Recently, newer imaging modalities such as real-time 3-dimensional
echocardiography and vascular imaging have increased the potential for the assessment and
understanding of cardiac and vascular pathophysiology. This may become essential in the
future for better initiation of therapy.
Stress echocardiography – From 2D to contrast 3D
Two-dimensional (2D) stress echocardiography is a non-invasive stress modality indicated for
the identification of coronary artery disease (CAD). The most important stress
echocardiographic methods are exercise- (as physiologic) and pharmacologic- (non-
physiologic) stress echocardiography. Regardless of the method applied, wall motion of left
ventricular (LV) segments is compared at different levels of stress (for instance baseline, low-
dose and peak dose at dobutamine stress) on several standardized LV views. The rationale for
2D stress echocardiography for detection of CAD is that cardiovascular stress will result in
myocardial ischemia, manifested as a regional wall motion abnormality (1,2). Although the
diagnostic and prognostic roles of 2D dobutamine stress echocardiography are well
established, this stress modality suffers from a number of limitations. Suboptimal diagnostic
accuracy may be caused by inadequate image quality, comparisons of non-identical LV wall
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segments at rest, low-dose, and peak stress, and smaller ischemic areas may be missed in the
limited available LV cross sections. The interpretation of this method is subjective with
different existing definitions of abnormality and considerable inter-observer and inter-
institutional diagnostic variability. The diagnostic accuracy of 2D dobutamine stress
echocardiography can be increased by the use of ultrasound contrast agents.
Three-dimensional (3D) echocardiography has been advocated as the ultimate
echocardiographic imaging modality since the start of the clinical application of
echocardiography. Theoretically real-time three-dimensional echocardiography (RT3DE) as
an ideal method for 3D echocardiography with online acquisition of a 3D dataset using matrix
transducers (Figure 2).
Figure 2 Size of the different 2D and 3D Philips transducers, from left to right: 3D-X3-1 (24
x 15 mm), 3D-X4 (24 x 20 mm) and 2D-S3 (24 x 15 mm).
Over the years several studies were published reporting the improved accuracy of RT3DE
over 2D imaging for measurements and calculations of left ventricular volumes and masses.
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Recent studies confirm the usefulness of newly developed software in the evaluation of
regional volumes and systolic function for each segment from the RT3DE-derived 3D
datasets. Theoretically, using RT3DE during stress testing its inherent advantages can
eliminate some of the current limitations of stress 2D echocardiography, and may result in an
improved diagnostic accuracy.
In the present thesis, our experience on stress 2D and contrast echocardiography and
our first experience with dobutamine stress contrast-enhanced RT3DE to evaluate wall
segments and their functions are reported. The optimal way for data acquisition during
contrast stress RT3DE was determined. The current technical and clinical limitations of stress
RT3DE are demonstrated, which need to be addressed before this method will become a
reliable clinical tool in the daily practise of the practising cardiologist.
Aortic stiffness measurements
Recent studies have demonstrated that arterial stiffness is an independent risk factor and a
predictor of cardiovascular mortality in a variety of diseases (3). Aortic stiffness is may be
more important than conventional risk factors and an important factor affecting coronary
perfusion. Direct measurement of arterial stiffness requires invasive techniques unsuitable for
routine clinical practice. Several different non-invasive methods can be used for the
characterization of aortic stiffness, most of them based on the direct measurement of the
pulsatile change in aortic diameter and conventional left brachial arterial systolic and diastolic
blood pressure measurement (4). With the knowledge of these parameters, a modulus/index
can be calculated characterising vascular stiffness. Routine transthoracic echocardiography is
a suitable method for the measurement of ascending aortic pulsatile change (Figure 3).
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Figure 3 Measurements of systolic (SD) and diastolic (DD) diameters of the ascending aorta
are shown on the M-mode tracing obtained at a level 3 cm above the aortic valve.
Storage diseases due to deposits can cause cardiac alterations, however, their effect on
vascular elasticity has never been investigated. It is also known, that aortic valve stenosis is
associated with vascular elasticity alterations, but long-term consequences of operation on
aortic stiffness have not been examined. The role of newly developed RT3DE in the
evaluation of regional vascular function was investigated.
References
1. Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and
diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol
1997;30:595-606.
2. Picano E, Mathias W, Jr., Pingitore A, Bigi R, Previtali M. Safety and tolerability of
dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo
Dobutamine International Cooperative Study Group. Lancet 1994;344:1190-1192.
3. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor
of all-cause and cardiovascular mortality in hypertensive patients. Hypertension
2001;37:1236-1241.
4. Stefanadis C, Stratos C, Boudoulas H, Kourouklis C, Toutouzas P. Distensibility of
the ascending aorta: comparison of invasive and non-invasive techniques in healthy
men and in men with coronary artery disease. Eur Heart J 1990;11:990-996.

Part A
Stress echocardiography –
From 2D to contrast 3D

CHAPTER 2
Factors Affecting Sensitivity and Specificity of
Dobutamine Stress Echocardiography
submitted
Marcel L. Geleijnse
Boudewijn J. Krenning
Attila Nemes
Eric Boersma
Johan G. Bosch
Tjebbe W. Galema
Folkert J. ten Cate
18
Abstract
Background. Clinical characteristics of patients, angiographic referral bias and several
technical factors may all affect the reported diagnostic accuracies of tests.
Aim of the study. To assess their influence on the diagnostic accuracy of dobutamine stress
echocardiography (DSE).
Methodology. The medical literature from 1991 to 2001 was searched for diagnostic DSE
studies and meta-analysis was applied to the 51 studies thus retrieved, including 5,739
patients. These studies were analyzed for year of publication, direct comparison with newer
technologies, gender and mean age of patients, inclusion of patients with prior myocardial
infarction, multi-vessel coronary disease, typical angina or beta-blocking medication, blinding
of tests, definition of angiographic disease, angiographic referral bias, addition of atropine,
definition of positive DSE and use of the biphasic response.
Results. DSE sensitivity was significantly related to the inclusion of patients with prior
myocardial infarction (85% vs. 75%, P <0.0001) and defining DSE already positive in case of
resting wall motion abnormalities rather than obligatory myocardial ischemia (86% vs. 80%,
P <0.001). The presence of referral bias adversely affected DSE specificity (77% vs. 84%, P
<0.005).
Conclusion. This analysis suggests that the reported sensitivity of DSE is higher and the
specificity lower than that expected in clinical practice because of the inappropriate inclusion
of patients with prior myocardial infarction, definition of positive DSE and the presence of
referral bias.
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Introduction
Dobutamine stress echocardiography (DSE) has been extensively studied as a diagnostic test
for the prediction of coronary artery disease (CAD). However, sensitivities and specificities
often differ greatly from one report to another. In one, often cited, review sensitivities ranged
from 54% to 96% and specificities ranged from 62% to 93% (1). Recently, controversy has
arisen regarding the inter-institutional stability of sensitivity and specificity and the wisdom
of applying DSE results reported in the literature to other clinical laboratories (2). Clinical
characteristics of patients, angiographic referral bias and several technical factors have all
been implicated as causes of differences in reported diagnostic accuracies for other stress
modalities such as exercise electrocardiography (3) and thallium scintigraphy (4). Therefore,
we analyzed which factors influenced the sensitivity and specificity of DSE by applying
meta-analysis on published diagnostic studies.
Methodology
Literature review. A Medline search for diagnostic DSE studies published up to 2001 using
the terms “dobutamine stress” and “coronary artery disease” was performed. In addition, we
reviewed the reference lists of review articles and eligible studies to complete the data search.
Excluded from this search were reports solely reporting on patients with poor
echocardiographic windows, left bundle branch block, hypertension and/or left ventricular
hypertrophy or prior myocardial infarction. To avoid duplication of data only the largest
report from an institution was considered, unless it was clear that different patients were
included. The remaining 58 reports (5-53) were retained for review. One of these reports (51)
described results of three separate study samples that had been based on different DSE
protocols and these samples were treated as independent observations. For reports describing
the value of atropine addition to DSE (27,33,36) only the dobutamine-atropine results were
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considered for analysis. For reports describing the value of second harmonic imaging (49)
only the fundamental imaging data were considered for analysis.
Statistical analysis. Sensitivity was defined as the number of true-positive tests divided by
the total number of patients with angiographically significant CAD. Specificity was defined as
the number of true-negative tests divided by the total number of patients without
angiographically significant CAD. Since the study group sizes differed greatly (Table 1), all
statistical tests were performed in a weighted fashion for testing sensitivities and specificities.
Comparisons were performed using the standardized normal distribution test and the F-test.
Multivariate analysis was performed by stepwise weighted linear regression. Statistical
significance was defined at the P <0.05 level and F >4.9.
Recording the variables. The values of the variables were noted before recording the
reported sensitivity and specificity. Two investigators (MLG and BJK) read the reports
independently and recorded the variables listed in the Tables. When a disagreement occurred
between the two investigators issues were resolved by consensus or a third investigator.
Discrete variables. These included the following: direct comparison with newer technologies
(magnetic resonance imaging, three-dimensional echocardiography or tissue Doppler
imaging), inclusion of patients with prior myocardial infarction, inclusion of patients with
beta-blocking medication (for analysis no information on beta-blocking medication was
interpreted as present), blind interpretation of DSE and coronary angiography (for analysis no
information regarding blinding was interpreted as not blinded), definition of angiographic
disease (50% versus 70% reduction in luminal diameter), presence of angiographic referral
bias (DSE results influencing the decision to undergo coronary angiography), addition of
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atropine, definition of positive DSE (dobutamine stress-induced or any wall motion
abnormality), number of wall motion abnormalities required for a positive test (one or two
segments, for analysis no information on the number of segments or statements like ‘a wall
motion abnormality’ were interpreted as one segment), and use of the biphasic response
(improvement of wall motion at low-dose followed by worsening of wall motion at high-dose,
for analysis no information on use of the biphasic response was interpreted as not used).
Continuous variables. These included the following: year of publication, mean age,
percentage of men, percentage of patients with prior myocardial infarction, percentage of
patients with multi-vessel CAD, percentage of patients with a history of typical angina,
percentage of patients receiving beta-blocking medication.
Results
Sensitivities and specificities (Table 1). For the 60 unique study groups in the 58 reports,
6,728 patients were studied with DSE and coronary angiography with sufficient data to record
sensitivity and specificity. Of these, 4,621 had angiographic CAD whereas 2,107 did not. A
total of 3,790 patients had true positive DSE resulting in a sensitivity of 0.820. There were
1,740 true negatives, allowing for a specificity of 0.826. Sensitivities and specificities for
each of the 60 study groups are reported in Table 1.
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Table 1. Group Characteristics Variables and Diagnostic Accuracies
Author Year Patients Mean Men Typical Angina CAD MVD CAD
Age (%) (%) (%) (%)
Afridi (5) 1994 45 62 99 - 84 69
Ahmad (6) 2001 90 - 47 32 64 41
Anthopoulos (7) 1996 120 75 60 43 74 58
Beleslin (8) 1994 136 50 85 36 88 8
Cain (9) 2001 114 62 75 - 74 47
Cohen (10) 1991 70 62 100 - 73 50
Dagianti (11) 1995 60 55 70 - 42 25
Daoud (12) 1995 76 60 58 - 86 55
Di Bello (13) 1996 45 53 73 87 84 42
Dionisopoulos (14) 1997 288 61 65 - 73 42
Elhendy (15) 1998 295 60 67 32 77 48
Epstein (16) 1992 61 59 70 - 89 48
Fathi (17) 2001 77 61 74 - 71 47
Gunalp (18) 1993 27 47 85 - 67 33
Hennessy (19) 1997 317 60 72 57 86 62
Ho (20) 1995 54 58 85 - 80 67
Ho (21) 1997 223 58 81 - 73 56
Hoffmann (22) 1993 60 57 77 - 80 35
Huang (23) 1997 93 61 77 - 72 52
Iwase (24) 1996 96 59 70 - 66 29
Kisacik (25) 1996 69 51 84 45 68 45
Lewis (26) 1999 92 58 0 - 27 16
Ling (27) 1996 183 69 35 - 81 60
Loimaala (28) 1999 60 55 67 65 73 30
Marcovitz (29) 1992 141 60 60 - 77 33
Martin (30) 1992 40 50 95 30 63 0
Marwick (31) 1993 217 58 72 65 65 34
Mazeika (32) 1992 50 54 88 - 72 48
McNeill (33) 1992 80 59 74 - 59 19
Nagel (34) 1999 172 60 71 - 63 41
Peteiro (35) 2001 41 63 78 - 78 49
Pingitore (36) 1996 110 60 83 - 84 46
Previtali (37) 1993 80 53 78 - 71 41
Sahin (38) 1994 65 58 71 71 65 40
Salustri (39) 1992 52 58 73 - 71 33
San Román (40) 1996 102 62 56 25 62 33
Santiago (41) 1994 77 67 70 - 69 0
Santoro (42) 1998 60 - - 17 55 35
Sawada (43) 1991 55 59 62 19 64 25
Schröder (44) 1997 99 57 80 - 89 41
Senior (45) 1994 61 63 72 - 72 49
Slavich (46) 1996 46 59 0 - 48 26
Smart (47) 2000 183 60 73 26 65 32
Sochowski (48) 1995 46 58 67 48 54 28
Sozzi (49) 2001 64 59 70 - 77 55
Steinberg (50) 1997 120 67 99 - 72 46
Takeuchi (51) 1999 178 63 77 - 65 31
Takeuchi (51) 1999 249 64 80 - 55 33
Takeuchi (51) 1999 511 63 71 - 53 25
Vitarelli (52) 1997 59 52 64 - 81 44
Wu (53) 1996 30 58 84 - 57 40
CAD = Coronary Artery Disease. MI = Myocardial Infarction. MVD = Multi Vessel Disease. - = Not Available
23
Table 1. (Continued) Group Characteristics Variables and Diagnostic Accuracies
Author Year Beta-blocker Beta-blocker MI MI Sensitivity Specificity
(%) (%) (%) (%)
Afridi (5) 1994 Yes 27 Yes 29 71 86
Ahmad (6) 2001 Yes 40 Yes 25 59 81
Anthopoulos (7) 1996 Yes 46 Yes 40 87 84
Beleslin (8) 1994 Yes 43 Yes 57 82 76
Cain (9) 2001 Yes 52 Yes 8 88 80
Cohen (10) 1991 Stopped 0 Yes 27 86 95
Dagianti (11) 1995 Stopped 0 No 0 72 97
Daoud (12) 1995 Yes 12 Yes 37 92 73
Di Bello (13) 1996 Stopped 0 No 0 76 86
Dionisopoulos (14) 1997 Yes 31 Yes - 87 89
Elhendy (15) 1998 Yes 35 Yes 52 75 87
Epstein (16) 1992 Yes 34 Yes - 91 57
Fathi (17) 2001 Yes 32 Yes 42 98 59
Gunalp (18) 1993 Stopped 0 No 0 83 89
Hennessy (19) 1997 Stopped 0 Yes 39 86 60
Ho (20) 1995 - - Yes 41 93 73
Ho (21) 1997 Yes - Yes 39 94 79
Hoffmann (22) 1993 Stopped 0 No 0 79 83
Huang (23) 1997 Yes 58 Yes 39 93 77
Iwase (24) 1996 Stopped 0 Yes 30 79 88
Kisacik (25) 1996 Stopped 0 Yes 30 94 86
Lewis (26) 1999 Yes 22 Yes 10 40 94
Ling (27) 1996 Yes 23 Yes 32 95 51
Loimaala (28) 1999 Yes 20 Yes 15 95 63
Marcovitz (29) 1992 Yes - Yes 11 96 66
Martin (30) 1992 Yes 33 Yes 35 76 60
Marwick (31) 1993 Yes 19 No 0 72 83
Mazeika (32) 1992 Stopped 0 Yes 26 64 93
McNeill (33) 1992 Yes 80 Yes 35 70 88
Nagel (34) 1999 No 0 No 0 74 70
Peteiro (35) 2001 - - Yes 41 81 89
Pingitore (36) 1996 Yes 5 Yes 27 84 89
Previtali (37) 1993 Stopped 0 Yes 19 79 83
Sahin (38) 1994 Stopped 0 Yes 23 79 87
Salustri (39) 1992 Yes 69 Yes 27 54 80
San Román (40) 1996 Yes 21 No 0 78 95
Santiago (41) 1994 Stopped 0 Yes - 79 67
Santoro (42) 1998 No 0 No 0 61 96
Sawada (43) 1991 Yes 51 No 0 89 85
Schröder (44) 1997 Stopped 0 Yes 53 89 82
Senior (45) 1994 Stopped 0 Yes 21 93 94
Slavich (46) 1996 Stopped 0 No 0 59 79
Smart (47) 2000 Yes 27 Yes - 87 91
Sochowski (48) 1995 Yes 37 No 0 68 81
Sozzi (49) 2001 Yes 50 Yes 55 78 73
Steinberg (50) 1997 Stopped 0 Yes 23 87 91
Takeuchi (51) 1999 Yes 16 Yes 55 84 89
Takeuchi (51) 1999 Yes 18 Yes 48 85 83
Takeuchi (51) 1999 Yes 16 Yes 50 85 82
Vitarelli (52) 1997 Stopped 0 Yes - 85 82
Wu (53) 1996 Yes - No 0 94 92
CAD = Coronary Artery Disease. MI = Myocardial Infarction. MVD = Multi Vessel Disease. - = Not Available
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Effect of patient characteristics (Table 1).
Extend of CAD. In 47 studies sensitivity of single-vessel versus multi-vessel CAD could be
calculated (mean sensitivity and specificity in these 5,464 patients was 0.819 and 0.836,
respectively). In 1,606 patients with single-vessel CAD sensitivity was 0.738. In 2,144
patients with multi-vessel CAD sensitivity was 0.880 (P <0.0001).
Prior myocardial infarction. The mean reported sensitivity and specificity from the 43 studies
that included patients with prior myocardial infarctions were 0.840 and 0.819, respectively.
For the 17 studies that excluded patients with prior myocardial infarctions sensitivity and
specificity were 0.745 (P <0.001) and 0.845, respectively. Of the continuous variables, the
percentage of patients with prior myocardial infarction and resting wall motion abnormalities
showed the highest correlation with DSE sensitivity (0.29 and 0.48, respectively). In the 780
myocardial infarction patients whose angiographic disease status and DSE result could be
inferred from the available data, sensitivity was 0.829 and specificity was 0.764. In the 2,161
non-myocardial infarction patients whose angiographic disease status and DSE result could be
inferred, sensitivity was 0.750 (P <0.0001) and specificity was 0.856 (P <0.01).
Other patient characteristics. Mean age, percentage of men and the use of beta-blocking
medication did not significantly affect DSE sensitivity or specificity.
Effect of publication factors (Table 1). The years that studies were published were not
correlated to DSE sensitivity or specificity
Effect of angiographic referral bias (Table 2). The presence of referral bias, present in 18
studies, negatively affected test specificity (0.781 vs. 0.826, P <0.005). Its effect on sensitivity
was not significant.
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Table 2. Referral bias and other Angiographic Factors
Author Referral Angiography Angiography Angiography
Bias Blinded CAD% cut off Quantitative
Afridi (5) No Yes 70 Yes
Ahmad (6) No - 50 No
Anthopoulos (7) Yes Yes 50 No
Beleslin (8) Yes Yes 50 Yes
Cain (9) No Yes 50 Yes
Cohen (10) Yes Yes 70 No
Dagianti (11) Yes Yes 70 Yes
Daoud (12) No - 50 No
Di Bello (13) Yes Yes 50 No
Dionisopoulos (14) No Yes 50 Yes
Elhendy (15) No - 50 Yes
Epstein (16) No Yes 50 No
Fathi (17) No Yes 50 Yes
Gunalp (18) Yes - 50 No
Hennessy (19) Yes Yes 50 No
Ho (20) Yes Yes 50 No
Ho (21) Yes - 50 Yes
Hoffmann (22) Yes Yes 70 Yes
Huang (23) Yes - 50 Yes
Iwase (24) Yes Yes 70 No
Kisacik (25) Yes Yes 50 No
Lewis (26) Yes Yes 50 Yes
Ling (27) No - 70 No
Loimaala (28) Yes - 50 No
Marcovitz (29) No - 50 Yes
Martin (30) Yes Yes 50 No
Marwick (31) Yes - 50 Yes
Mazeika (32) Yes Yes 70 No
McNeill (33) Yes - 50 No
Nagel (34) Yes Yes 50 No
Peteiro (35) Yes Yes 50 No
Pingitore (36) Yes Yes 50 Yes
Previtali (37) Yes Yes 50 No
Sahin (38) Yes Yes 50 No
Salustri (39) Yes Yes 50 Yes
San Román (40) Yes - 50 Yes
Santiago (41) No - 70 No
Santoro (42) Yes - 70 Yes
Sawada (43) No Yes 50 Yes
Schröder (44) Yes - 50 Yes
Senior (45) Yes Yes 50 No
Slavich (46) Yes - 50 Yes
Smart (47) Yes Yes 50 Yes
Sochowski (48) Yes Yes 50 No
Sozzi (49) No - 70 Yes
Steinberg (50) Yes Yes 70 No
Takeuchi (51) Yes Yes 50 Yes
Takeuchi (51) Yes Yes 50 Yes
Takeuchi (51) Yes Yes 50 Yes
Vitarelli (52) No - 70 No
Wu (53) Yes Yes 50 Yes
Abbreviation see Table 1.
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Effect of technical angiographic factors (Table 2).
Definition of stenosis. There was no difference in diagnostic accuracy between the 45 studies
in which 50% diameter stenosis was used as cut off for significant CAD compared to the 15
studies in which 70% diameter stenosis was used as cut off for significant CAD.
Blinding of reading. Blinding of the coronary angiogram, present in 40 studies, did not
significantly affect sensitivity and specificity.
Quantitative scoring of stenosis. Quantitative scoring of the coronary angiogram, present in
33 studies, did not significantly affect sensitivity and specificity. In the 20 studies in which
reading of the coronary angiogram was not blinded non-quantitative (visual) scoring did also
not significantly affect sensitivity and specificity.
Effect of technical stress echocardiographic factors (Table 3).
Blinding of reading. Because DSE was in all but five studies blinded the effect of blinding
could not be established.
Comparison with newer technologies. In the 12 studies assessing the value of newer
technologies in direct comparison with DSE, sensitivity tended to be lower (0.794 vs. 0.833, P
<0.10) and specificity was significantly lower (0.765 vs. 0.831, P <0.001).
DSE protocol. In the 17 studies in which resting wall motion abnormalities already
constituted a positive DSE, sensitivity was higher compared to the 43 studies in which a
dobutamine stress-induced wall motion abnormality (myocardial ischemia) was necessary to
define DSE positive (0.863 vs. 0.788, P <0.001) with a loss in specificity (0.805 vs. 0.840, P
<0.05). Addition of atropine, use of the biphasic response and the requirement of only one
(versus two) ischemic segment for a positive DSE did not increase DSE sensitivity. When
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Table 3. Stress Echocardiographic Factors
Author Comparison with Stress Echo Dobutamine Atropine Definition of Segments Biphasic
New Technology Blinded Dose Addition Positive Test Required Response
Afridi (5) No Yes 40 No Rest or Stress - No
Ahmad (6) Yes Yes 40 Yes Stress - -
Anthopoulos (7) No Yes 40 No Stress 1 No
Beleslin (8) No Yes 40 No Stress 1 -
Cain (9) Yes Yes 40 Yes Rest or Stress - Yes
Cohen (10) No Yes 40 No Stress - No
Dagianti (11) No Yes 40 No Stress 1 -
Daoud (12) No - 30 No Rest or Stress 1 No
Di Bello (13) No Yes 40 Yes Stress 1 -
Dionisopoulos (14) No Yes 40 Yes Rest or Stress 2 Yes
Elhendy (15) No Yes 40 Yes Stress 1 Yes
Epstein (16) No Yes 50 No Rest or Stress 1 -
Fathi (17) Yes Yes 40 Yes Stress - Yes
Gunalp (18) No Yes 30 No Stress 1 No
Hennessy (19) No Yes 50 Yes Rest or Stress 2 -
Ho (20) No Yes 40 No Stress 1 No
Ho (21) No Yes 40 Yes Stress 2 No
Hoffmann (22) No Yes 40 Yes Stress - No
Huang (23) No Yes 40 Yes Rest or Stress - Yes
Iwase (24) No Yes 40 No Stress - No
Kisacik (25) No Yes 40 Yes Stress 1 No
Lewis (26) No Yes 40 Yes Stress 1 Yes
Ling (27) No Yes 40 Yes Rest or Stress 1 -
Loimaala (28) No Yes 40 No Stress 1 -
Marcovitz (29) No Yes 30 No Rest or Stress - No
Martin (30) No Yes 40 No Stress 2 No
Marwick (31) No Yes 40 No Rest or Stress 1 No
Mazeika (32) No Yes 20 No Stress 1 No
McNeill (33) No Yes 40 Yes Stress 1 No
Nagel (34) Yes Yes 40 Yes Stress 1 Yes
Peteiro (35) Yes Yes 40 Yes Rest or Stress - Yes
Pingitore (36) No Yes 40 Yes Stress 1 No
Previtali (37) No Yes 40 No Stress 1 No
Sahin (38) No Yes 30 No Stress 1 No
Salustri (39) No Yes 40 No Stress 1 No
San Román (40) No Yes 40 Yes Stress 1 No
Santiago (41) No - 40 No Rest or Stress 1 -
Santoro (42) No Yes 40 Yes Stress - -
Sawada (43) No Yes 30 No Stress - Yes
Schröder (44) No Yes 40 Yes Stress 2 -
Senior (45) No Yes 40 No Rest or Stress - -
Slavich (46) No Yes 40 Yes Stress 1 -
Smart (47) No Yes 40 Yes Rest or Stress 2 No
Sochowski (48) No Yes 40 No Stress - -
Sozzi (49) Yes Yes 40 Yes Stress 1 -
Steinberg (50) No Yes 40 No Stress 1 No
Takeuchi (51) No Yes 30 No Rest or Stress 1 -
Takeuchi (51) No Yes 40 No Rest or Stress 1 -
Takeuchi (51) No Yes 40 Yes Rest or Stress 1 -
Vitarelli (52) No - 50 No Stress 1 Yes
Wu (53) No Yes 40 No Stress 1 No
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only the 43 studies that required myocardial ischemia for a positive DSE were included,
atropine did also not increase sensitivity.
Multivariate analysis. At multivariate analysis, prior myocardial infarction (F = 6.4, P
<0.001) and definition of positive DSE (F = 5.3, P <0.01) independently influenced
sensitivity. Only the presence of referral bias (F = 6.5, P <0.005) independently influenced
specificity.
Discussion
This meta-analytical review indicates that patient characteristics, referral bias and technical
factors (such as the definition of positive DSE) all significantly affect the reported sensitivity
and specificity of DSE.
Patient characteristics. The inclusion of patients with prior myocardial infarction
significantly increased the sensitivity of DSE. This may be the result of more extensive and/or
severe CAD or the definition of positive DSE (see later). Since the diagnosis of CAD in
patients with known prior myocardial infarction is nearly certain, the inclusion of such
patients in investigations purporting to predict CAD seems inappropriate.
Ischemia during DSE is more likely in patients with more extensive CAD. This was
confirmed by the significant relation between the number of diseased vessels and the
likelihood of dobutamine-stress induced wall motion abnormalities. This finding confirms
earlier reports (1) and support the use of DSE to identify patients at higher risk of multi-vessel
CAD. The value of other CAD characteristics such as lesion severity (54,55), lesion type
(56,57) or the presence of collaterals (56,58) could not be assessed because information
concerning these variables was lacking in virtually all included diagnostic DSE studies.
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We had expected that in studies which included patients on beta-blocking medication
DSE sensitivity would be lower because dobutamine effects (predominantly mediated by
beta-receptors) are obviously limited, resulting in a lesser increase in rate-pressure product
(59, 60). Surprisingly, in these studies peak mean heart rate (uncorrected for age) was almost
identical to studies that not included patients on beta-blocker (119 vs. 121 beats per minute)
and consequently beta-blocker use did not affect DSE sensitivity. This latter finding may also
be explained by more extensive and/or severe CAD in patients on beta-blockers (61) and the
use of atropine in most of the studies including patients on beta-blockers (60). However, in
studies in which atropine was not used, beta-blocker medication also did not result in a
markedly lower peak mean heart rate (108 vs. 110 beats per minute) and consequently did not
affect DSE sensitivity.
Unlike exercise electrocardiography (3) and exercise thallium scintigraphy (4), female
gender did not affect DSE sensitivity or specificity. This finding is consistent with other
publications focusing on the role of DSE in women (14, 62).
Referral bias. Referral bias is present when angiography is guided by results of the stress test
under investigation. Because patients are predominantly send for coronary angiography with
positive DSE this may increase sensitivity and decrease specificity of DSE. Unfortunately,
regardless of study design it is almost impossible to completely avoid referral bias. Clearly,
diagnostic DSE studies based on patients who are retrospectively selected because they
underwent coronary angiography and DSE within a certain time frame (usually 6-12 weeks)
will suffer from referral bias. However, prospective studies based on patients recruited from a
coronary angiography waiting list are also not free from referral bias. These patients are
usually listed because of some other positive stress test and thus are more likely to have a
positive DSE. Finally, chest pain patients prospectively scheduled for coronary angiography
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and DSE usually represent those with more serious complaints (typical angina rather than
non-anginal chest pain) and are therefore not truly representative for the whole spectrum of
patients encountered at the outpatient clinic. Nevertheless these limitations, those studies that
attempted to avoid referral bias by not allowing the results of DSE to affect the decision to
perform coronary angiogram had significantly higher specificities than studies that did not.
Therefore, specificity in normal control patients will be somewhat higher than that obtained in
most DSE studies.
Publication factors. We expected that technical advances would make sensitivity and
specificity increase with time. However, we found no significant increase in test sensitivity
between 1991 and 2001. Also, specificity was unaffected by time although this may be caused
by the influence of referral bias in more recently published studies.
Stress echocardiographic technical factors. In studies in which rest wall motion
abnormalities defined DSE already positive sensitivity was significantly higher. As mentioned
before, since the diagnosis of CAD in patients with rest wall motion abnormalities is nearly
certain, the inclusion of such patients in investigations purporting to predict CAD seems
inappropriate.
Previous studies have shown that addition of atropine to dobutamine by increasing
heart rate significantly increased DSE sensitivity without a loss in specificity (27, 33, 36). In
our analysis, despite a very significant higher peak mean heart rate (130 vs. 109 beats per
minute), the addition of atropine did not affect DSE sensitivity. Also, when we considered
only DSE studies in which dobutamine stress-induced wall motion abnormalities (myocardial
ischemia) were necessary for a positive DSE there was a tendency toward a higher DSE
sensitivity in atropine studies.
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Use of the biphasic response did not affect test sensitivity. Previous studies have
shown that in patients with rest wall motion abnormalities use of the biphasic response
significantly increased DSE sensitivity (63, 64). With respect to the biphasic response one
problem is to determine exactly in which studies it was used. In one third of all studies it was
unclear whether or not the biphasic response was used (Table 3). We assumed that the
biphasic response was only used when it was clearly reported or could clearly be deducted.
The validity of our conclusion that the biphasic response did not affect test sensitivity rests on
this assumption. Another problem is that in some studies none of the patients had rest wall
motion abnormalities and that in some studies including patients with rest wall motion
abnormalities these latter already constituted a positive DSE. However, exclusion of these
latter studies did not change our analysis.
Also, defining DSE positive in case of dobutamine stress-induced wall motion
abnormality in one rather than two segments did not increase sensitivity of DSE. A previous
study has shown that in particular in patients with prior myocardial infarction the use of at
least two segments reduces sensitivity without a significant improvement in specificity (65).
Our results may be different by our assumption that studies in which the description was
unclear, the usual definition of the requirement of only one segment for a positive test was
used.
Sensitivity and specificity of DSE were lower when the test was directly compared in
the same patients with newer technologies such as dobutamine magnetic resonance imaging,
three dimensional echocardiography or tissue Doppler imaging. It is an intriguing finding that
for many stress modalities (i.e. stress radionuclide angiography) initially excellent results are
reported, whereas in comparisons with newer tests results of the previously considered state-
of-the-art test are not comparable to the initial reported results.
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Other technical factors.When the result of one test influences the interpretation of another,
a higher concordance between the two is expected. Since DSE reading was not blinded in
only three studies we could not reliably assess the effect of non-blinding DSE. With respect to
blinding of the coronary angiogram one problem is to determine exactly in which studies
authors were blinded. Since the authors never reported the non-blinding of test analysis, we
therefore assumed that studies used blinded analysis only when it was reported as such. In
contradiction to reports on exercise thallium scintigraphy (4), blind reading of the coronary
angiogram did not affect DSE sensitivity. Again, the validity of our conclusion that blinding
does not affect DSE sensitivity significantly rests on this assumption.
Clinical and research applications. Clinicians should be aware of the expected diagnostic
sensitivity and specificity of DSE. A large amount of data on this topic is available in the
medical literature. However, one should always question whether these diagnostic accuracies
obtained in top centers by experts in the field can be applied to your own clinical laboratory.
Moreover, clinical characteristics of the patients studied, referral bias and several technical
factors may all cause differences in diagnostic accuracies in real life. Our results indicate that
the reported sensitivity of DSE is higher and the specificity lower than that expected in
clinical practice because of the inappropriate inclusion of patients with prior myocardial
infarction, definition of positive DSE and the presence of referral bias.
As stated many years ago by Detrano et al. (4), investigators in the field of diagnostic
testing should more conform to methodological standards in conducting research and
reporting their results (4, 66-68). Inappropriate patients such as those with prior myocardial
infarction should be excluded or treated separately. Study groups should be explicitly defined,
with careful description of patients characteristics and patients should not be excluded
because they are expected to give false-positive or false-negative results. All tests (DSE and
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coronary angiography) should be analyzed blindly, and referral bias should be avoided.
Reviewers should use these standards in their criticisms and publication decisions. No report
should be refused solely because the results are negative or disappointing since this practice
has probably inflated the diagnostic accuracy of many tests.
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Abstract
Background. Today’s aggressive dobutamine-atropine stress echocardiography (DASE)
protocol and expanding indications with inclusion of sicker patients have raised concerns
about the safety of this stress modality.
Aim of the study. To investigate the incidence of complications during DASE and to provide
pathophysiological insight and treatment options.
Methods. A MedLine search on studies reporting complications during DASE was performed
with the search terms “safety”, “complication”, “side effect” or “adverse effect” in the Title.
Data on incidence of complications were tabulated and calculated as mean percentage and
range. Also, case reports describing complications were identified.
Results. Nineteen DASE safety studies with over 400 patients, including a total of 31 724
patients, were identified. Life-threatening complications (death, cardiac rupture, myocardial
infarction, cerebrovascular accident, asystole, ventricular fibrillation and sustained ventricular
tachycardia) occurred in approximately each one of 400 patients. This complication rate was
in particular driven by the occurrence of sustained ventricular tachycardia, exclusion of this
specific complication resulted in a complication rate of one in 1 000 tests. Death was only
once reported in the safety studies due to ventricular fibrillation, but three times in case
reports due to cardiac rupture after a recent inferior myocardial infarction. Patients with a
history of myocardial infarction and/or impaired left ventricular function had a four times
higher risk of cardiac rupture, ventricular fibrillation or myocardial infarction. Some of the
most important complications did occur up to one hour after dobutamine discontinuation.
Conclusions. DASE carries a definite, albeit small, risk. This risk should always be carefully
weighted against the expected diagnostic or prognostic benefit.
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Introduction
Dobutamine stress echocardiography was clinically introduced in the mid-eighties (1).
Indications for this stress modality rapidly expanded from diagnosing coronary artery disease
(CAD) into risk stratification of patients undergoing vascular surgery, patients with chronic
coronary artery disease, unstable angina, acute or chronic myocardial infarction (MI) or
valvular heart disease as well as the assessment of myocardial viability in patients with severe
left ventricular dysfunction. Thus, dobutamine stress has been applied to progressively more
complex, older and higher risk patients. Additionally, stress protocols became more
aggressive, with higher dobutamine doses in combination with atropine (2). Although
generally regarded as a safe stress modality, serious complications do occur. In this review we
will describe the incidence, pathophysiology and treatment of complications induced by
dobutamine-atropine stress echocardiography (DASE).
Methods
A MedLine search on dobutamine stress echocardiography studies reporting complications
was performed with the search terms “dobutamine stress” and “safety” or “complication” or
“side effect” or “adverse effect” in the Title. By this initial search 47 studies were identified.
From this initial search we excluded studies using other imaging modalities (magnetic
resonance imaging, nuclear perfusion, transesophageal echocardiography), those specifically
addressed to safety in specific patients (valvular heart disease, transplant patients, left
ventricular thrombus, aneurysm, internal cardiac defibrillator). Also excluded were studies
limited by a small number (<400) of patients because such smaller studies are more likely to
be influenced by publication bias. Additional safety papers were included after screening the
references of the selected studies and by the authors’ extensive own knowledge. To avoid
duplication of data only the largest report from a single centre was included. Data on
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incidence of complications were thus obtained from nineteen studies (3-21), for a total of
31724 patients (Table 1). All these included studies fulfilled the final inclusion criterion of
reporting at least the major complications death, acute MI, ventricular fibrillation and
sustained ventricular tachycardia. For each study, death and the life-threatening complications
cardiac rupture, acute MI, cerebrovascular accident, asystole, ventricular fibrillation and
sustained ventricular tachycardia were noted. Other complications noted were atropine
intoxication, atrioventricular (AV) block, supraventricular arrhythmias (regular
supraventricular tachycardia, atrial fibrillation and atrial flutter), hypotension and
hypertension. In addition, the incidence of wall motion abnormalities and hypotension and
hypertension as a test endpoint was noted. To assure the quality of data extraction this was
independently done by two physicians (MLG, BJK). All calculations on cumulative (mean)
complication risks were done according to a weighted analysis in which the total number of
patients with a complication was divided by the total number of patients at risk for a
complication. Also, references were given to case reports and studies specifically dealing with
a particular complication.
POTENTIALLY LIFE-THREATENING COMPLICATIONS
Death
Incidence: Less than 0.01% (0.003%, range 0.00 to 0.01%). Case reports (22-24).
Pathophysiology: In DASE safety studies death was only once reported due to ventricular
fibrillation (21). In three case reports lethal cases of cardiac rupture were described (22-24).
Treatment: See other specific sections for treatment of potentially fatal complications.
Cardiac Rupture
Incidence: Less than 0.01% (0.003%, range 0.00 to 0.01%). Case reports (22-25).
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Pathophysiology: Cardiac rupture was reported in five patients undergoing DASE with akinetic
or dyskinetic inferior myocardium resulting from a recent (4-12 days old) inferior MI. In all
five cases, the patient suddenly developed (atypical) chest pain and lost consciousness with
pulseless electromechanical dissociation. In three of five patients cardiac rupture was fatal (22-
24). Strong inotropic stimulation of necrotic and thinned myocardium may increase wall stress
to such an extent that rupture results in that part of the myocardial wall with the least
resistance. Of note, low-dose dobutamine provides already strong inotropic stimulation, as was
shown in two case reports with ruptured myocardium at doses of only 10 Pg/kg/min (22,25).
Whether the inferior myocardial wall is more prone to rupture is controversial (26,27).
Diagnosis should be easy by looking for sudden development of pericardial effusion.
Treatment: Discontinue dobutamine infusion. Emergency pericardiocentesis and surgery.
Myocardial Infarction
Incidence: 0.03% (range 0.00 to 0.10%). Case reports (28-33).
Pathophysiology: DASE may cause MI through different mechanism. In a coronary artery with
an unstable atherosclerotic plaque, increment of heart rate and contractility may mechanically
increase shear forces resulting in plaque disruption and thrombosis. Additionally, dobutamine
has been shown to induce platelet activation and aggregation (34) and D1-mediated coronary
vasoconstriction, which may even paradoxically be exacerbated by administration of a non-
selective E-blocker (see section on coronary spasm). Dobutamine stress-induced expansion of a
sinus of Valsalva aneurysm, with compression of a coronary artery, was once reported as a
potential mechanism for MI (32).
Treatment: Discontinue dobutamine infusion. Consider immediate coronary angiography
followed by angioplasty or thrombolysis (35).
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Cerebrovascular Accident
Incidence: Less than 0.01% (0.009%, range 0.00 to 0.10%). Complication specific publication
(36).
Pathophysiology: DASE may cause a cerebrovascular accident through different mechanism.
Increment of heart rate and blood pressure may mechanically increase shear forces across an
aneurysmal arterial wall leading to haemorrhagic stroke (36). Ischemic stroke (including
transient ischemic attack) may be caused by the same mechanisms as described in the previous
section on MI. Additionally, ischemic stroke may occur in the setting of dobutamine stress-
induced hypotension (see later) in the presence of a high-grade carotic artery stenosis (5).
Treatment: Discontinue dobutamine infusion. Hospitalisation in stroke unit. Consider
immediate imaging with magnetic resonance imaging or computed tomography and
thrombolysis (37).
Cardiac Asystole
Incidence: Less than 0.01% (0.003%, range 0.00 to 0.03%). Case reports (38-40).
Pathophysiology: The syndrome of sinus bradycardia with or without hypotension is well
known during DASE. Eventually this may lead to asystole lasting 6-8 seconds (13,38).
Although in an early report sinus node deceleration was linked to ischemia in the inferior
myocardial wall (41), a powerful cardio-inhibitory vagal reflex seems a more likely
mechanism. This reflex, known as the Bezold-Jarisch reflex, is a neurally mediated mechanism
in which vigorous myocardial contraction stimulates intramyocardial mechanoreceptors,
resulting in sympathetic withdrawal and enhanced parasympathetic activity (42). Alternatively,
it was suggested that prohibition of oral intake before DASE may lead to volume depletion,
and experimental data have demonstrated that in presence of a reduced cardiac volume E1-
adrenergic stimulation can elicit paradoxical bradycardia (43). In contradiction to the earlier
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described life-threatening complications, patients with asystole usually had good baseline left
ventricular function with a hyperdynamic response to dobutamine and usually absence of
myocardial ischemia (38-40).
Treatment: Discontinue dobutamine infusion. Immediate intravenous bolus of atropine (0.5-2
mg).
Ventricular Fibrillation
Incidence: 0.04% (range 0.00 to 0.18%). Case reports (33,44-46).
Pathophysiology: All but two patients (15,33) described in the literature with available data
had impaired left ventricular function and all had evidence for (usually severe) myocardial
ischemia at DASE (4,6,15,44-47). Furthermore, except for one patient with ST-segment
elevation, non-significant CAD and suspected coronary spasm (46), all patients who underwent
coronary angiography showed left main or three-vessel CAD (4,6,12,33). So, ventricular
fibrillation seems mainly to occur in patients with structural heart disease (presence of
persistent factors such as scar tissue) in combination with inducible, dynamic factors such as
severe and/or extensive myocardial ischemia and possibly electrolyte disturbances (see also
next section on other ventricular arrhythmias).
Treatment: Discontinue dobutamine infusion. Cardiopulmonary resuscitation was in all but one
patient (21) successful.
Sustained Ventricular Tachycardia
Incidence: 0.16% (range 0.00 to 0.78%). Complication specific publications (48-50). Case
reports (51-53).
Pathophysiology: Dobutamine may provoke ventricular arrhythmias by several mechanism.
Dobutamine has differential effects on action potential duration (54), QRS-duration and QTc-
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interval (55) in normal and ischemic myocardium. The abnormal dispersion of conduction in
adjacent areas of ischemic and non-ischemic myocardium thus created may be important in E-
receptor mediated (re-entry) arrhythmogenesis. Additionally, dobutamine may increase
intracellular calcium concentration by second messenger cyclic adenosine monophosphate
(56). Increased intracellular calcium has been shown to increase automaticity in ventricular
myocardium, and provoke triggered activity in the form of delayed afterdepolarizations (57).
Finally, E-receptor stimulation reduces plasma potassium level, which may temporarily
predispose patients to ventricular arrhythmias (58). Many safety studies have analysed clinical
predictors for these arrhythmias. Ventricular arrhythmias have quite consistently been related
to impaired left ventricular function (16,17,47-50,59) and a history of ventricular arrhythmias
(47,49,59) but not to atropine addition (11,21,47,49,50) or myocardial ischemia
(11,13,17,18,21,47-50,60). It should be noticed, however, that none of these studies made a
distinction between non-sustained and sustained ventricular arrhythmias (probably because of
the small number of the latter) and the incidence of ventricular tachycardias may be
overestimated because of difficulties in differentiation with supraventricular tachycardia with
aberration (48).
Treatment: Discontinuation of dobutamine infusion (ventricular arrhythmias are usually brief
and self terminating). Intravenous E-blocker (metoprolol 5-10 mg over a 5-minute period).
Intravenous procainamide (10 mg/kg body weight over a 5-minute period) or lidocaine (bolus
of 50 mg) in E-blocker resistant sustained ventricular tachycardia. Cardiovert if
hemodynamically unstable.
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OTHER RHYTHM AND CONDUCTION DISTURBANCES
Supraventricular Arrhythmias
Incidence: Premature atrial complex 9.4% (range 1.2 to 27.8%). Supraventricular tachycardia
1.6% (range 0.0 to 7.0%). Atrial fibrillation 1.0% (range 0.3 to 2.2%). Complication specific
publication (50).
Pathophysiology: Little is known about the mechanism of dobutamine stress in the induction of
supraventricular arrhythmias. In one study (50), supraventricular arrhythmias occurred more
frequently in patients with more extensive impairment of left ventricular function. The
associated increase in left atrial size and pressure in such patients are well known predictors for
these arrhythmias. In another study (8), supraventricular arrhythmias occurred more frequently
in elderly patients.
Treatment: Discontinuation of dobutamine infusion (supraventricular arrhythmias are usually
brief and self terminating). Intravenous E-blocker (metoprolol 5-10 mg, dose may be increased
in case of existing high maintenance dose), verapamil (10 mg over 10 minutes, dose may be
reduced in case of previous use of a beta-blocking drug or hypotension) or digoxine (bolus of
0.5 mg). Digoxin effects may take several hours and are therefore less useful for rapid rate
control (61), but may be preferred in patients with left ventricular dysfunction. In regular
supraventricular tachycardias, adenosine (intravenous bolus of 6 or 12 mg) may be helpful for
diagnosis by induction of AV-block and may actually end circus movement tachycardias.
Adenosine has a half-life of only 2 seconds so that adverse reactions (facial flushing, dyspnea)
last only a short time (62). Cardiovert if hemodynamically unstable.
Atrioventricular Block
Incidence: 0.23% (range 0.03 to 0.68%). Complication specific publication (63).
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Pathophysiology: Transient second or sometimes third degree AV-block may be induced by
several mechanism such as myocardial ischemia (the conduction system is mainly supplied by
the right coronary artery and more distally also by the left anterior descending artery), the
Bezold-Jarisch reflex and latent abnormalities in the His-Purkinje system. In a detailed study of
12 patients with dobutamine stress-induced second degree AV-block by Hung et al. (63), the
incidence of AV block was 4.0%, pointing to a higher incidence than that reported in the safety
studies. All six patients with second degree AV-block Mobitz type II (usually located in the
His bundle or bundle branches) had CAD (usually left anterior descending artery or two vessel
CAD). In all but one patient AV-block occurred concomitantly with the onset of new wall
motion abnormalities. After successful coronary revascularization AV block could not be
induced by repeat DASE. In the six patients with second degree AV block Mobitz type I
(Wenckebach block, usually located in the AV node) the relation with CAD and myocardial
ischemia was less clear. Vagal mediated effects by the earlier described Bezold-Jarisch reflex
(see section on asystole) could be a contributing factor is these patients. This assumption was
supported by positive head-up tilt testing in all three patients with second degree AV-block
Mobitz type I without CAD. AV-block is less common during this vagal reflex than sinus
bradycardia, sinoatrial block or sinusarrest, probably because these sinus node problems
protect the AV node. Finally, dobutamine enhances AV nodal conduction and may thus
unravel latent abnormalities in the more distal His-Purkinje system.
Treatment: In Mobitz type II discontinuation of dobutamine infusion (of note, atropine may
actually worsen subnodal block). In Mobitz type I (Wenckebach) block intravenous bolus of
atropine (0.5 mg, may be repeated up to 2.0 mg) if necessary.
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CORONARY SPASM
Incidence: True incidence unknown, 0.14% in one safety study (8). Case reports (46,64-71).
Complication specific publication (72).
Pathophysiology: Coronary spasm during dobutamine stress is believed to result from D1-
receptor mediated coronary vasoconstriction (73), in particular in patients with endothelial
dysfunction due to smoking, hypertension or diabetes (74,75). Systolic ‘spasm’ (or better
compression) during dobutamine stress may be caused by myocardial bridging (71). In one
study (72), including 51 patients with angina at rest accompanied with electrocardiographic
ST-segment elevation, non-significant CAD and proven spasm (induced with acetylcholine),
dobutamine stress provoked ST-segment elevation in 7 patients (14%). In another study (65),
ST-segment elevation and wall motion abnormalities became evident only post dobutamine-
stress after the administration of propranolol and it has been suggested that non-selective E-
blockers may paradoxically exacerbate spasm by blocking the E2- receptor mediated coronary
vasodilatative effects of dobutamine. Alternatively, coronary spasm may be caused by
hyperventilation in an anxious patient (76). Coronary spasm should be suspected in patients
with dobutamine stress-induced ST-segment elevation in non-infarct leads and severe new wall
motion abnormalities, although these may be absent in distal spasm (70), in combination with
non-significant lesions at coronary angiography. ST-segment elevation in non-infarct leads has
also been linked to transmural myocardial ischemia due to severe CAD (77-81). The final
diagnosis of coronary spasm can only be confirmed at coronary angiography with ergonovine,
acetylcholine, or dobutamine provocation (70,72).
Treatment: Sublingual nitroglycerin or nifedipine first rather than E-blocking agents (68,69)
because of a small risk for exacerbation of spasm with a E-blocker (65). Long-term treatment
with calcium-channel blockers. Risk factor modulation. Drug (cocaine) abstinence.
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DISTURBANCES IN BLOOD PRESSURE
Hypotension
Incidence: As test endpoint 1.8% (range 0.2 to 7.6%). Dependent on definition, the overall
incidence is much higher, a decrease >20 mm Hg is noticed in approximately 20% of patients
(82,83). Complication specific publications (82-90).
Pathophysiology: Hypotension may result from an inadequate increase in cardiac output to
compensate for an expected decrease in systemic vascular resistance, and/or a disproportionate
decrease in systemic vascular resistance. An inadequate increase in cardiac output may be due
to inadequate contractile reserve, severe ischemic left ventricular dysfunction, or fixed or
dynamic left-sided obstructive heart disease. Dynamic left ventricular cavity obliteration due to
strong inotropic stimulation was proposed as an important cause for reduced cardiac output and
hypotension (87), but in later studies conflicting results have been reported for this mechanism
as an important cause for hypotension (85,88-90). The second mechanism, a disproportionate
decrease in systemic vascular resistance may be due to the earlier described Bezold-Jarisch
reflex or rarely an allergic reaction to dobutamine (see later section on dobutamine
hypersensitivity). The consistent absence of histories of prior MI or congestive heart failure
(82,83), ischemia (16,82-86) or CAD (16,82,83,86) in studies with heterogeneous patients is
indirect evidence of a dobutamine-induced hypotension mechanism that is primarily based on
an excessive decrease in systemic vascular resistance, instead of a mechanism principally
involving inadequate cardiac output in most patients. In patients with impaired left ventricular
function (and thus a lesser role for the Bezold-Jarisch reflex) there is some evidence that
contractile reserve plays a more important role in the pathogenesis of hypotension (59,91,92)
and that hypotension has adverse prognostic value (91).
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Treatment: Discontinue dobutamine infusion. Trendelenburg position. Rapid fluid infusion if
symptomatic. In combination with sinus bradycardia exclude inferior wall ischemia and
consider intravenous bolus of atropine (0.5-2 mg).
Hypertension
Incidence: As test endpoint 1.0% (range 0.2 to 3.5%). Complication specific publication 1.0%
(93).
Pathophysiology: Stress-induced hypertension normally constitutes an end point for test
termination because of safety concerns (94). Only two studies (11,93) analysed the clinical
characteristics of patients with a marked hypertensive response. Such patients more often had a
history of systemic hypertension, higher resting blood pressure and were more often on
treatment with E-blockers compared to patients without a hypertensive response. These
findings underscore the importance of adequate blood pressure control before dobutamine-
atropine stress to avoid non-diagnostic tests. Alternatively, it was proposed (93) to earlier use
atropine in patients with a marked hypertensive response because of only a mild additional
effect on blood pressure and a marked chronotropic effect.
Treatment: Discontinue dobutamine infusion.
DIRECT SIDE-EFFECTS OF DOBUTAMINE-ATROPINE
Atropine Intoxication
Incidence: 0.03% (range 0.00 to 0.17%). No case reports.
Pathophysiology: Atropine intoxication is a central anticholinergic syndrome in which atropine
acts on central nervous system cholinergic receptors causing altered mental status (confusion,
delirium, hallucinations) or prolonged sedation for several hours. This syndrome is more
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common in elderly patients and generally requires a dose of atropine of several milligrams
(95).
Treatment: Physostigmine 1 to 2 mg intravenously can reverse the central atropine effects. Its
administration also acts as a diagnostic test: rapid improvement rules out other causes of
confusion such as cerebral stroke. Alternatively, it was proposed (96) to avoid atropine in the
elderly and to give glycopyrrolate, a anticholinergic drug that does not cross the blood-brain
barrier and so cannot cause a central anticholinergic syndrome.
Dobutamine Extravasation
Incidence: Only once reported in two patients in a safety study (5), but probably underreported.
Case reports in continuous infusion (97,98).
Pathophysiology: Dobutamine accumulation in subcutaneous tissue can cause local
vasoconstriction by stimulation of D1-receptors which may result in limb ischemia (99) and
during longer infusion even in necrosis (97). Dobutamine accumulation in subcutaneous tissue
may also cause a local hypersensitivity reaction (see next section).
Treatment: Discontinuation of dobutamine infusion. Elevate involved extremity. Local
injection of 5 to 10 mg phentolamine mesylate in 10 to 15 ml saline, a reversible, non-selective
D-receptor antagonist.
Dobutamine Hypersensitivity
Incidence: Only three patients described in safety studies (6,15). Case reports, during
continuous infusion, on local dermal lesions (100-102) and asthma (103).
Pathophysiology: Dobutamine solution contains sodium bisulfite that may cause allergic-type
reactions with systemic symptoms and/or signs such as bronchospasm, flushing, tingling,
pruritus, urticaria, angio-edema and hypotension or local dermal lesions characterized by
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erythema, pruritus, cellulites and phlebitis with or without bullae formation at the side of the
injection (104).
Treatment: Discontinuation of dobutamine infusion. Antihistamine therapy.
Discussion
Today’s aggressive DASE protocol and expanding indications with inclusion of sicker patients
have raised concerns about the safety of this stress modality (105). In the present meta-
analysis, potentially life-threatening complications (cardiac rupture, acute MI, cerebrovascular
accident, asystole, ventricular fibrillation and sustained ventricular tachycardia) occurred in 80
patients, of whom one died, accounting for one complication in approximately each 400 tests
(Table 2).
Table 2. Incidence of Major Complications during 31,724 Dobutamine-Atropine
Stress Echocardiographic Studies.
Complication Number of
Patients
Incidence
Rate
Death 1 1 : 30 000
Cardiac rupture 1 1 : 30 000
Asystole 1 1 : 30 000
Cerebrovascular accident 3 1 : 10 000
Myocardial infarction 10 1 : 3 000
Ventricular fibrillation 13 1 : 2 500
Sustained ventricular tachycardia 51 1 : 600
Total major complications 80 1 : 400
It is important to notice that for exercise stress testing, dipyridamole stress echocardiography
and dipyridamole stress scintigraphy lower complication rates were reported of one in
approximately each 1100 (106), 1400 (107) and 1600 (108) tests, respectively. Several reasons
may account for this difference. Patients referred for DASE are usually unable to exercise
adequately and such patients are known to have a higher incidence and extent of CAD
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(109,110). Also, the high-dose dobutamine-atropine stress protocol has a strong potential to
induce myocardial ischemia. Exercise-induced ischemia may limit work load in a patient and
this may prevent the development of severe ischemia during exercise stress. Pharmacological
stress with the vasodilator dipyridamole primarily creates blood flow heterogeneity and true
ischemia in only a limited number of patients with significant CAD (111). Finally, as described
earlier, dobutamine may provoke ventricular arrhythmias by several unique mechanism.
Indeed, the striking difference in complication rate is to a great extent caused by the high
incidence rate of sustained ventricular tachycardia (and to a lesser extent also ventricular
fibrillation) during dobutamine-atropine stress. When sustained ventricular tachycardia is
excluded from our analysis, the complication rate is one complication in approximately each
1000 tests for dobutamine-atropine stress, each 1500 tests for exercise stress (106), and each
1700 test for both dipyridamole stress studies (107,108). Obviously, it is still essential to
optimise the safety profile of DASE. This may be achieved by giving attention to patient
selection, identification of patients at relative high-risk for complications, personnel issues and
DASE protocol.
Patient selection. Safety starts with verification of test indication. Stress testing for diagnostic
purposes is only useful in patients with an intermediate pre-test probability of CAD (112). In
patients with a high pre-test probability of CAD there may be a case for prognostication but
only then when DASE results really will affect patient management decisions. Subsequently,
contraindications to DASE should be identified. Absolute contraindications include for
dobutamine symptomatic severe aortic stenosis, acute aortic dissection, unstable coronary
syndromes and hypertrophic cardiomyopathy and for atropine narrow-angle glaucoma,
myasthenia gravis, and obstructive uropathy or gastrointestinal disorders. Relative
contraindications include electrolyte abnormalities, intraventricular thrombus, intracranial or
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abdominal aneurysm, known severe ventricular arrhythmias, high-degree AV-block and
uncontrolled hypertension or atrial fibrillation. Although small DASE safety reports have been
published in patients with a history of ventricular arrhythmias (113), left ventricular apical
thrombus (114), intracranial aneurysms (36) and abdominal aneurysms (115), vasodilator stress
testing seems intuitively the stress test of choice in such patients. After verification of
indication and exclusion of contraindications, the procedure as well as side effects and
potential complications should be explained to the patient. In patients at relative high-risk for
complications (see next section) it may be good practice to obtain written informed consent by
the patient. It should be noticed that in some countries dobutamine and atropine have even not
been approved for pharmacological stress testing, making written informed consent by the
patient necessary.
Identification of high-risk patients. Although severe complications can be sudden and
unpredictable, clearly not each patient carries the same risk. All patients with cardiac rupture
had a recent inferior MI, although it is controversial whether this particular myocardial region
is relative susceptible for rupture (26,27). Ventricular fibrillation almost exclusively occurred
in patients with impaired left ventricular function with induction of extensive myocardial
ischemia. Identification of patients at relatively high-risk for acute MI may be more difficult.
Although all but three patients had a history of CAD (usually prior MI), about half of the
infarctions occurred in a myocardial territory without evidence for myocardial ischemia. This
is consistent with the angiographic study by Ambrose et al. (116) in which the culprit vessel
leading to acute MI had a mean initial stenosis of only 34%. Dobutamine-atropine stress will
normally not induce myocardial ischemia in a myocardial territory supplied by a vessel with
such a minor stenosis (117). As with other stress test, the relative risk of cardiac rupture,
ventricular fibrillation or acute MI was four times higher in patients with a history of MI and/or
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impaired left ventricular function. Therefore, the risk-benefit ratio of DASE in these patients
should always be carefully evaluated.
Personnel. The current era of cost containment makes it challenging to dedicate physician time
solely to the supervision of a time consuming test such as DASE. Paramedical supervision of
exercise testing has been well established in the literature (118) and in selected patients this is
allowed by the ACC/AHA Guidelines for Exercise Testing (119). Some have proposed to train
nurse sonographers to fill the supervisory role during DASE (12). However, patients referred
for DASE are usually not able to exercise adequately and therefore a priori at higher risk for
induction of severe myocardial ischemia and complications. Furthermore, the experience with
nurse sonographers to fill the supervisory role is sparse (5,12). Although some complications
are largely independent of the operator’s experience, there is a relation between the number of
complications and the years of experience and volume of a centre (21). Therefore, we fully
agree with Lattanzi et al. (105) that a physician with knowledge of the incidence,
pathophysiology and treatment of complications should attend the test. In case of
complications the physician should be able to prove that indications were appropriate, the
protocol followed standard guidelines, the patient was aware of the inherent risks of the
procedure, and that standard treatment was provided in a timely fashion.
DASE protocol. Controversy exists about the use (and definition) of stress-induced wall
motion abnormalities as a test endpoint. This is clearly reflected in the 0% - 32% range in
which this endpoint was used in the DASE safety studies. One may question whether
continuation of DASE after the first clear signs of myocardial ischemia provides additional
diagnostic or prognostic information and whether it is safe. There may be little loss of
information when an examination is stopped because of signs of ischemia in one coronary
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territory since the timing of ischemia (ischemic threshold) provides already excellent
diagnostic (120) and prognostic (121) information. It is not known whether continuing DASE
and potentially inducing ischemia in a multivessel distribution carries additional and
independent information over the ischemic threshold. In patients with prior MI, ischemia
outside the infarction territory may certainly be a test endpoint because this usually confirms
multivessel CAD. Concerning the safety, it is important to note that provocation of severe
myocardial ischemia played an important role in patients with ventricular fibrillation. The
incidence of ventricular fibrillation was highest in studies with the most conservative use of
this endpoint (17,47) and lowest in studies with the most liberal use of this endpoint (14,16).
It is well known that some life-threatening complications such as ventricular fibrillation
(45), cerebrovascular accident (21) and in particular acute MI (4,5,11,21,28-31,60) can occur
after dobutamine discontinuation, mostly within 20 minutes but up to 60 minutes has been
described, despite its short half-life time and antidote administration. Thus, in particular in
patients at risk for these complications, close cardiologic monitoring is required during the
recovery phase and these patients should be instructed not to leave the hospital within one hour
and immediately report any possible symptom of acute MI.
CONCLUSIONS
Potentially life-threatening complications during DASE occur in approximately one in each
400 studies. This relatively high complication rate is in particular driven by the occurrence of
sustained ventricular tachycardia. Some of the important complications may occur within one
hour after discontinuation of dobutamine infusion. Patients with a history of MI and/or
impaired left ventricular function are at much higher risk for complications. The risk-benefit
ratio of DASE should always be carefully evaluated.
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Abstract
Objective. To study the adverse effects of SonoVue® echo contrast in a consecutive series of
cardiac patients.
Design. During a 4-year period all adverse effects of SonoVue® contrast agent applied for
diagnostic cardiac echocardiographic studies were noted.
Setting. Tertiary referral center.
Patients. Consecutive patients referred for a diagnostic SonoVue® contrast cardiac
echocardiographic study.
Results. During 352 consecutive cardiac SonoVue® studies, seven patients (2.0%)
experienced adverse effects. Four patients (1.1%) had mild allergic reactions causing skin
erythema and mild sinus tachycardia, three patients (0.9%) experienced a severe allergic
reaction resulting in (non-fatal) anaphylactic shock.
Conclusions. The reported incidence of adverse effects of SonoVue® echo contrast in this
consecutive series of cardiac patients seems markedly higher than those reported in a company
post-marketing analysis and await confirmation.
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SonoVue® (Bracco, Milan, Italy) is a blood pool ultrasound contrast agent based on
microbubbles stabilised by a phospholipids shell and filled with sulphur hexafluoride gas (1,2).
It is isotonic to human plasma and claimed to be devoid of antigenic potential, as it does not
contain any proteineous material. SonoVue® has been approved in Europe and other countries
for the improvement in endocardial border delineation during echocardiography and other,
non-cardiac applications. However, throughout Europe a number of serious allergic reactions
with probable secondary cardiovascular problems have been reported to national and
international registry authorities (3,4). Three of these reports included even fatal outcome soon
after the administration of SonoVue® in patients with severe coronary artery disease. Despite
questions about the causal relationship, the European Medicines Agency (EMEA) recently
took precautionary measures to limit the use of SonoVue® in patients with cardiac disease
(www.emea.eu.int/humandocs/Humans/EPAR/ SonoVue/SonoVue.htm). As a result of the
EMEA interventions, SonoVue® is contra-indicated in cardiac patients with an (suspected)
acute coronary syndrome, recent percutaneous coronary intervention, acute or chronic severe
(NYHA class III/IV) heart failure or severe cardiac arrhythmias. In our cardiac department we
have been using SonoVue® since mid 2001. Because of safety concerns we systematically
reviewed in a consecutive series of patients all adverse effects of SonoVue® in our
echocardiographic laboratory.
Mild adverse reactions
During a 4-year period 352 SonoVue® echo contrast studies were performed in 274 patients
for a variety of reasons (5,6). One hundred and ninety-eight patients underwent only one
SonoVue® study, whereas 77 patients underwent multiple SonoVue® studies. Mild adverse
reactions, including skin erythema and mild sinus tachycardia, were seen in four patients
(1.1%). These mild reactions were present in 2 out of the 198 patients (1.0%) who received
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SonoVue® only once and 2 out of the 76 patients (2.6%) who received SonoVue® twice. All
four patients were successfully treated with intravenous clemastine and hydrocortisone.
Severe adverse reactions
During the same 4-year period an additional three patients (0.9%), who all underwent
SonoVue® echocardiography for the first time, experienced a severe anaphylactic reaction.
Case 1 (August 21, 2001)
An 80-year-old man known with hypertension and recent (3 weeks earlier) carotid stenting was
referred to dobutamine stress echocardiography for risk stratification before aortic abdominal
surgery. Medical treatment included acetyl salicylic acid, clopidogrel, calcium antagonist, beta-
blocker and diuretics. The patient did not experience angina during exercise nor were there
symptoms of heart failure. Because of poor quality of the echo window, SonoVue® contrast
was used. During recording of the resting echo images (with 0.75 ml SonoVue®) the patient
developed extensive skin erythema and anaphylactic shock with a decrease in blood pressure
from 150/70 to 70/30 mmHg. Clemastine 2 mg and hydrocortisone 100 mg were immediately
injected intravenously and volume resuscitation (300 ml gelofusine) was applied. After 10
minutes, the patient fully recovered and the blood pressure returned to a normal level (145/80
mmHg). After a night observation in the clinical department he was discharged the next day.
Dobutamine stress technetium-99m SPECT, performed at the outpatient clinic, did not show
reversible perfusion defects and the patient was cleared for vascular surgery.
Case 2 (February 24, 2005)
A 68-year-old woman known with Pompe’s disease (a lysosomal glycogen storage disease due
to D-glucosidase deficiency) was referred for SonoVue® contrast echocardiography because of
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an ongoing study protocol to investigate cardiac function in these patients. Left ventricular
end-diastolic diameter was 46 mm and ejection fraction was 83%. Due to Pompe’s disease the
patient was in a poor clinical condition with a severely limited exercise tolerance and need for
intermittent use of a respirator machine. After bolus injection of 0.5 ml and two repeat
injections of 0.25 ml of SonoVue® the patient experienced tinnitus and dizziness. Blood
pressure decreased from 140/80 to 70/40 mm Hg and sinus rate decreased from 90 to 50 beats
per minute after which the patient became subconscious. Clemastine 2 mg and hydrocortisone
100 mg were immediately injected intravenously and volume resuscitation (150 ml gelofusine)
was applied. After 15 minutes the patient completely recovered and returned to the
neurological department.
Case 3 (September 15, 2005)
A 34-year-old man known with familiar non-ischemic dilated cardiomyopathy was referred for
SonoVue® contrast echocardiography to exclude non-compaction cardiomyopathy (5). Left
ventricular end-diastolic diameter was 69 mm and ejection fraction was 37%. The patient was
in stable NYHA heart failure class I-II for years without evidence for high filling pressures.
Medical treatment included ACE inhibition, beta-blocker and diuretics. After bolus injection of
0.5 ml and an additional 0.25 ml of SonoVue® the patient experienced a heat sensation with
nausea and extensive skin erythema after which sinus bradycardia developed. Despite
immediate intravenous injection of clemastine 2 mg and hydrocortisone 100 mg the patient
went into anaphylactic shock with extreme brady-arrhythmia (<30 beats per minute), lost
conscious and started gasping. After a short-lasting resuscitation procedure (cardiac massage
and manual ventilation) of approximately three minutes the patient fully recovered. The patient
was observed in the clinical department from which he was discharged the same day. Ten
hours after discharge, the patient experienced pain in multiple joints lasting for two days.
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Immunological analysis revealed a type III allergic reaction without identification of a specific
allergen.
Clinical implications
Throughout Europe a number of serious allergic reactions with probable secondary
cardiovascular problems have been reported to national and international registry authorities
(3,4). These allergic reactions may be caused by the SonoVue® sulphur hexafluoride gas or the
shell component polyethylene glycol (macrogol 4000) (7-9). In a Bracco company post-
marketing analysis in 157,838 patients, 19 non-fatal severe (0.01%) and 3 fatal (0.002%)
complications after the use of SonoVue® were reported. Obviously, the risks and benefits of
SonoVue® should be weighted and these should be compared with other diagnostic tests.
Unfortunately, clinical outcome studies for SonoVue® are not yet published. So, this leaves us
with two basic questions. What is the risk of SonoVue® and how does this risk compare with
other diagnostic modalities? The complication rates in the registry are, although somewhat
higher compared to Optison® (4), not higher than the complication rates of intravascular
contrast media used in radiology (10,11). This is an important finding because patients referred
for a cardiac study are in general at a higher risk to develop secondary cardiovascular
problems. We should, however, realize that it is difficult for a post-marketing analysis to define
a test as low-risk because of potential underreporting of complications. Therefore, it is essential
that consecutive series of patients should be prospectively monitored for complications in
institutions. In our study population of 352 consecutive cardiac studies, seven patients (2.0%)
experienced adverse effects, including anaphylactic shock in three patients (0.9%). These
numbers seem higher than those reported in the registry and await confirmation. For this
moment, we strongly emphasize the EMEA guideline that it is recommended to keep the
patient under close medical supervision during and for at least 30 minutes following the
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administration of SonoVue®. Intravenous anti-allergic and anaphylactic drugs (H1 and H2-
antihistamines, corticosteroids and epinephrine) should be available in the echo room in
addition to standard resuscitation equipment (12). Apart from the existing contra-indications
caution is advised in all patients, and in particular those patients with a compromised cardio-
pulmonary status.
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Abstract
Two-dimensional stress echocardiography is a non-invasive imaging stress modality with a
continuously evolving spectrum of indications. Although the diagnostic and prognostic roles of
stress echocardiography are well established, it is widely known that stress echocardiography
suffers from a number of limitations. Real-time three-dimensional echocardiography has been
advocated to solve some of these problems. The aim of the present state-of-the-art paper is to
discuss the benefits and current limitations of this new stress methodology.
Introduction
Two-dimensional (2D) stress echocardiography is a non-invasive stress modality with a
continuously evolving spectrum of indications. One of the most important indications is the
identification of patients with coronary artery disease (1). For this purpose, wall motion of left
ventricular (LV) segments is compared between rest, low-dose, and peak stress on several
standardized LV views. The rationale for the use of 2D stress echocardiography is that
cardiovascular stress will in the presence of significant coronary disease result in myocardial
ischemia, manifested as a regional wall motion abnormality. Although the diagnostic and
prognostic roles of 2D stress echocardiography are well established (1, 2), it is widely known
that stress echocardiography suffers from a number of limitations. Suboptimal diagnostic
accuracy may be caused by inadequate image quality, comparisons of non-identical LV wall
segments at rest, low-dose, and peak stress, and smaller ischemic areas may be missed in the
limited available LV cross sections. Also, interpretation of 2D stress echocardiography is
subjective with different existing definitions of abnormality and considerable inter-observer
and inter-institutional diagnostic variability (3). Three-dimensional (3D) stress
echocardiography has been advocated to improve the suboptimal diagnostic accuracy.
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ACQUISITION AND ANALYSIS OF 3D IMAGES
From one single apical window the full LV volume data set can be acquired. This process may
be facilitated by use of two displayed reference 2D images, such as an apical four-chamber and
an orthogonal view. Full LV volume is acquired by scanning of four subvolumes of ~20° x 80°
during four (Philips iE33) or seven (Philips Sonos 7500) consecutive, electrocardiographically
triggered, heartbeats. These LV subvolumes are automatically integrated by the system into
one pyramidal data set of ~80° x 80°, incorporating full LV volume (Figure 1).
Figure 1 During 3D data acquisition four 20 x 80° sectors are scanned during four consecutive
heart beats that are integrated automatically into a 80 x 80° pyramid.
All desired LV anatomical images can be cropped out of the pyramidal volumetric data set
after which regional LV wall motion can be assessed. Analysis of LV wall segments can be
done according to the 17-segment model recommended by the American Society of
Echocardiography (4), but with 3D more detailed models (incorporating for example short
axis views) can also be designed. For off-line analysis, the TomTec 4D Echo-View system
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(TomTec GmbH, Unterschleissheim, Germany) or the Qlab system (Philips Medical Systems,
Andover, Massachussets, USA) can be used.
BENEFITS OF RT3DE IMAGING
RT3DE has several advantages over conventional 2D echocardiographic methods. While 2D
echocardiography makes incorrect geometric assumptions about LV morphology, 3D
echocardiography sees the LV as it truly is (5). The introduction of new generation RT3DE
systems has improved 3D data acquisition and LV volume analysis to a great extent.
Importantly, compared to other 3D imaging modalities such as magnetic resonance imaging or
computed tomography, RT3DE is easy to learn and a less time consuming imaging modality.
As pointed out on earlier, RT3DE has excellent correlation with cardiac magnetic resonance
imaging for evaluation of LV volume, mass and ejection fraction with comparable
reproducibility (6-8).
With stress RT3DE, at each stress level only one 3D data acquisition from one window
is needed instead of multiple 2D data acquisitions from multiple windows. This makes a 3D
examination faster than conventional 2D stress imaging. This allows for faster acquisition
protocols and/or repeated acquisitions to optimize image quality. From the acquired 3D
volumetric data sets, matching views at baseline and at different levels of stress can be selected
for a precise comparison of identical segments. Importantly, foreshortened acquired LV walls
can be corrected by rotating the 3D data set. RT3DE allows analysis of similar segments in
more detail from different planes simply by cropping and rotating the 3D volumetric data set
helping the identification of small ischemic LV regions (9) (Figures 2 and 3).
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Figure 2 Overview of wall motion produced automatically from a 3D dataset at rest showing
apical 4-chamber view (AP4CH, left, top), apical 2-chamber (AP2CH, right, top), cross-
sectional short-axis (left, bottom) and reconstructed 3D image (right, bottom).
Figure 3 Comparison of left ventricular short axis images at the papillary muscle level in a
patient who underwent stress magnetic resonance imaging (MRI) and stress real-time three-
dimensional echocardiography (RT3DE). Observe the great similarity in images between
RT3DE and MRI.
Some investigators have claimed a higher success rate of adequate image acquisition in the
apical region with stress RT3DE compared to 2D echocardiography and the accuracy of
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diagnosing myocardial ischemia in the left anterior descending territory tended to be higher by
stress RT3DE than by stress 2D echocardiography in one study (9).
RT3DE also allows a more accurate measurement of LV ejection fraction compared to
2D echocardiography (10). Changes in LV ejection fraction during stress may be helpful for
the diagnosis of coronary disease and estimation of prognosis (11). Another advantage of
RT3DE can be that after the identification of some anatomical landmarks, RT3DE allows
automatic calculation of regional volumes that can be another indicator for abnormality
(Figure 4).
Figure 4 Real-time three-dimensional echocardiography allows the analysis of regional
(segmental) wall motion and calculation of volume/time curve of the left ventricle based on
semi-automated contour tracings. The volume/time curves of each colour-coded segment in the
bull`s eye view (right bottom) are represented in the volume/time curve (bottom)
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Finally, RT3DE allows anyplane evaluation of the LV helping to create short-axis views at
different LV levels that may be easier to understand by other (non-cardiologists) physicians.
CURRENT LIMITATIONS OF STRESS RT3DE
Notwithstanding its great opportunities, at this moment stress RT3DE has a number of
technical limitations. We report on some of these that we encountered with the Philips Sonos
7500 system with the X-4 matrix transducer. Most limitations also apply for the other available
3D systems.
Spatial volume and spatio-temporal resolution. The primary restriction for RT3DE is the
limited spatial volume coverage, or actually the trade-off between spatial volume, spatial
resolution and temporal resolution (3D frame rate). In analogy to 2D echo, there is a trade-off
between frame rate, image depth and number of beams. This limitation is directly related to a
physical constant: the speed of sound in human tissue (~1450 m/s). It takes 0.14 msecs to
transmit an ultrasound pulse and receive its echoes from a depth of 10 cm. Therefore, only
approximately 7500 beams can be acquired per second. With specialized beam forming,
multiple beams can be acquired simultaneously, but this goes at the cost of additional artefacts
and is bound to practical limits (12). For practical use in echocardiography, the temporal and
spatial resolution should satisfy certain minimum requirements. This means that the 3D
volume imaged within a time frame is limited. This is the volume we see in the ‘live 3D’
mode, which is the true real-time 3D mode of the system.
In real practice, to cover the whole LV, four complete heartbeats containing four LV
subvolumes have to be recorded. These four LV subvolumes are stitched together to form the
total pyramidal LV volume (Figure 1). Actually, 3D image acquisition with the Philips Sonos
7500 system takes seven heart cycles to complete, because some processing is required before
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the next beat can be acquired. Slice stitching may give rise to discontinuities at the slice edges
(Figure 5).
Figure 5 Slice stitching may give rise to discontinuities at the slice edges.
3D image slice discontinuities may be aggravated by transducer or patient motion (prominent
breathing motion at peak stress), variations in heart rate (during stress the latest recorded beat
may be shorter in duration), arrhythmias and imperfect electrocardiographic triggering.
Unfortunately, irregular heart rhythms (extra-systolic beats, atrial fibrillation) are not seldom
encountered during dobutamine stress (1).
Poor anterior wall visualization. Visualization of the LV anterior wall can sometimes be
difficult even during 2D echocardiography. Unfortunately, the anterior wall is inadequately
visualized in a considerable number of our stress 3D examinations. In our initial experience
approximately half of the anterior wall segments are inadequately visualized (13). Others have
reported better results for imaging of the anterior wall (14). However, it should be noticed that
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in these studies patients were selected on their image quality (15). As shown in Figure 6, these
problems are related to the relatively large footprint of the X4 matrix transducer compared to a
standard S3 transducer (24 x 20 vs. 24 x 15 mm), leading to rib shadowing.
Figure 6 Size of the different Philips transducers, from left to right: 3D-X3-1 (24 x 15 mm),
3D-X4 (24 x 20 mm) and 2D-S3 (24 x 15 mm).
One could try to make an additional recording from a parasternal window to cover the basal
and mid anterior wall, but this would eliminate most of the fast recording advantages of
RT3DE. Better results may be expected with the new, smaller X3-1 transducer that has a size
comparable to the standard S3 transducer (24 x 15 mm).
Quad-screen display. A practical obstacle for the use of stress RT3DE is the lacking
possibility of TomTec and Qlab software to display the different stress stages simultaneously
in a quad-screen display. Recently, we developed a simple extension program (Stress4Qlab)
that allows simultaneous, synchronized viewing of multiple 3D datasets. Information on this
program is available upon request. It is to be expected that built-in support for 3D stress echo
will be available soon.
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Contrast imaging. It has been demonstrated that echo contrast improves endocardial border
visualization during stress 2D echocardiography (16). Because of the earlier described relative
poor quality of 3D images contrast may be an essential part of stress RT3DE (Figure 7).
Figure 7 Improvement of endocardial delineation by the use of contrast agent (compare
unenhanced (left side) and contrast-enhanced (right side) left ventricular long-axis planes).
However, with contrast LV opacification, stitching artefacts may become aggravated and
some additional artefacts may appear (17). During the seven-beat acquisition period contrast
opacification of the LV may decay significantly because of microbubble insonification. This
problem may be less when the contrast agent is continuously infused rather than given as
repeated boluses or when the acquisition period is shortened to four beats, as is possible with
the new Philips iE33 system. This was apparent in several cases, where neighbouring slices
had different levels of contrast opacification, causing sharp transitions at the slice edges.
Furthermore, the differentiation between contrast and tissue is not as good as in standard 2D
harmonic imaging, because the matrix transducer has a limited relative bandwidth, and is
therefore less suitable for harmonic imaging.
A minor additional problem is the brighter appearance of the first frame of a beat
compared to the next frames. This is attributable to the fact that there is no acquisition at the
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second, fourth and sixth heartbeat, so the first frame of each beat is acquired after a period
without insonification. In later frames some contrast will be progressively destroyed by the
ultrasound pulse and contrast brightness will be lower.
CLINICAL 3D STRESS ECHOCARDIOGRAPHIC STUDIES
Three-dimensional echocardiography has been available for several years using time-
consuming reconstruction techniques. However, recent advances in transducer technology and
front-end data processing have brought real-time 3D echocardiography (RT3DE) into clinical
practice. In several studies, resting RT3DE was as accurate as magnetic resonance imaging
(MRI) in the evaluation of LV morphology and function (5-8).
At this moment, only a few studies have been reported on the clinical value of stress
RT3DE (see Table 1). In the first published stress RT3DE study by Zwas et al. the feasibility
of a Volumetrics Medical Imaging RT3DE system (Volumetrics, Durham, North Carolina,
USA) during treadmill stress was investigated (18). In this study, 89% of LV segments were
visible at peak stress when only an apical window was used to record the 3D data set. This
number increased to 98% if in addition to the apical window also a parasternal window was
used. Ahmad et al. used the same Volumetrics RT3DE system with dobutamine as stressor
(19). They confirmed that stress RT3DE is feasible and superior interobserver agreement and
diagnostic accuracy was described for stress RT3DE due to more complete visualization of all
LV segments in multiple views. Matsumura et al. compared stress 2D echocardiography with
RT3DE using a second-generation Philips Sonos 7500 3D echocardiography system (Philips
Medical Systems, Andover, Massachusetts, USA) equipped with a matrix-array X4 transducer
with 3000 active elements (9, 20). In this study, exercise Tl-201 single-photon emission
computed tomography served as the reference standard for myocardial ischemia (9). They
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confirmed that stress RT3DE offers rapid and simple acquisition of the entire LV wall motion
and provides feasible and accurate assessment of myocardial ischemia, comparable to stress
2D echocardiography. Takeuchi et al. examined the feasibility of contrast-enhanced
dobutamine stress RT3DE compared to stress 2D echocardiography (14). A significantly
higher number of good quality, interpretable segments for wall motion analysis was described
with contrast-enhanced dobutamine stress RT3DE. However, the concordance for the
identification of wall motion abnormalities between stress 2D echocardiography and RT3DE
was only modest, in particular because of discordant results noted in the LAD territory.
Unfortunately, no gold standard for coronary ischemia was available. The beneficial effects in
terms of image quality and interobserver agreement for wall motion scoring of contrast-
enhanced dobutamine stress RT3DE was recently confirmed by Pulerwitz et al. (21) and our
group (13) (see Table 1). The somewhat lower visibility of contrast-enhanced myocardial
segments in our study might be explained by the non-selection of our patients (15). Currently,
alternative RT3DE systems (GE Vingmed Vivid 7 system with 3V transducer, Philips iE33
system with the X3-1 transducer) are already available and it is expected that systems from
other vendors will be introduced soon. Although in some of these first studies stress RT3DE
looks promising for the detection of ischemia, more investigations are needed, because the
number of studies is limited.
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CONCLUSIONS AND FUTURE DEVELOPMENTS
Although stress RT3DE may be well clinical feasible according to some studies (9,18,19,21),
in our opinion this imaging modality is currently still hampered by some major technical
limitations. However, most of these limitations may be handled with or may be overcome in
the near future. Analysis software will be adapted to support stress RT3DE with proper choice
of corresponding viewing planes in rest, low-dose and stress with simultaneous synchronized
viewing. In addition, future transducers will have larger bandwidth and thus will be more
suitable for harmonic imaging and contrast and the transducer footprint size will be further
reduced. The 3D-X3-1 transducer on the new iE33 system already has a much smaller footprint
that may circumvent rib shadowing.
Multibeat frame composition and limited spatial resolution actually form the major
technical limitations. To overcome this, more ultrasound beams have to be processed in
parallel. This requires technological innovation, but it will ultimately result in true RT3DE LV
visualization. This will seriously extend the possibilities and clinical value of RT3DE, not just
for stress RT3DE.
Ultimately, the inherent advantages of stress RT3DE will eliminate some of the current
limitations of stress 2D echocardiography, and may result in an improved diagnostic technique
(Table 2).
Table 2. Benefits of RT3DE compared to 2D echocardiography
2D echocardiography RT3DE
Wall motion + ++
Contrast ++ +
Volumes + ++
Regional volumes - +
+ means clinically available, - means clinically not available
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Moreover, with the development of more advanced automated border detection software, we
can also expect a decrease in inter-observer variability associated with the visual scoring of
segmental wall motion. Also the learning curve to interpret wall motion analysis may become
easier because of the 3D nature of the images. If 3D image quality can be brought to a
comparable level as 2D image quality, stress RT3DE may be more suitable for such automated
analysis than stress 2D echo because 3D images offer a higher information content with
complete LV visualization. Provided that all these technical improvements will occur stress
RT3DE may become an important diagnostic test of the future.
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Abstract
Dobutamine stress echocardiography is an accepted tool for the diagnosis of coronary artery
disease. Some investigators have claimed that three-dimensional imaging improves the
diagnostic accuracy of dobutamine stress echocardiography. The purpose of the present
investigation was to examine the role of echo contrast in the improvement of segmental quality
and inter-observer agreement during stress real-time 3D echocardiography (RT3DE). The
study comprised 36 consecutive patients with stable chest pain referred for routine stress
testing. The 3D images were acquired with a RT3DE system with X4 matrix array transducer.
All available reconstructed 2D segments were graded as optimal, good, moderate and poor.
Wall motion was scored as normal, mild hypokinesia, severe hypokinesia, akinesia and
dyskinesia. At peak stress, 466 of the 612 segments (76%) could be analysed during
conventional RT3DE. With contrast-enhanced RT3DE, the number of available segments
increased to 553 (90%). The image quality index during conventional RT3DE was 2.2, while
with contrast-enhanced RT3DE 3.1. With conventional RT3DE, the two independent observers
agreed on the diagnosis of myocardial ischaemia in 85 of 108 coronary territories (79%, N =
0.26). With contrast-enhanced RT3DE, it increased to 95 of 108 coronary territories (88%, N =
0.59). Study agreement on myocardial ischaemia was present in 26 of 36 studies (72%, N =
0.43) with conventional RT3DE, and in 32 of 36 studies (89%, N = 0.77) with contrast-
enhanced RT3DE. In conclusion, during stress RT3DE contrast-enhanced imaging
significantly decreases the number of poorly visualized myocardial segments and improves
interobserver agreement for the diagnosis of myocardial ischemia.
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Introduction
Dobutamine stress echocardiography is an accepted tool for the diagnosis of coronary artery
disease (1). The interpretation of the echocardiographic images, however, is critically
dependent on the quality of the recordings and the experience of the observer (2). Some
investigators have claimed that three-dimensional imaging improves the diagnostic accuracy of
dobutamine stress echocardiography (3-5). However, one of the main limitations of three-
dimensional imaging is the inherently lower image quality compared to two-dimensional
imaging. Left ventricular (LV) opacificating contrast agents have been successfully applied
during 2-dimensional dobutamine stress echocardiography to improve endocardial border
delineation (6). The use of intravenous ultrasound contrast improves endocardial border
visualization, leading to a more accurate interpretation of wall motion abnormalities (6). The
purpose of the present investigation was to examine the role of echo contrast in the
improvement of LV segmental quality and interobserver agreement during stress real-time
three-dimensional echocardiography (RT3DE).
Patients and methods
Patient population. The study comprised 36 consecutive patients in sinus rhythm with chest
pain referred for stress testing. Baseline clinical characteristics of the patients are presented in
Table 1. Beta-blockers were used in 22 patients (61%). The study was approved by the
institutional review board and all patients gave informed consent.
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Table 1 Clinical and demographic characteristics (n = 36)
Variable Subjects
Age (years) 57 ± 13
Men 24 (67%)
Diabetes mellitus 9 (25%)
Hypertension * 18 (50%)
Hypercholesterolemia † 14 (39%)
Current smoker 4 (11%)
Prior acute myocardial infarction 10 (28%)
Prior coronary bypass surgery 2 (6%)
Prior coronary angioplasty 7 (19%)
* Defined as systolic blood pressure t140 mm Hg and/or diastolic blood pressure t90 mm
Hg and/or the use of antihypertensive medication.
† Defined as total serum cholesterol t230 mg/dl and/or serum triglycerides t200 mg/dl or
the use of a lipid-lowering agent.
Dobutamine-atropine stress protocol. Dobutamine was administered through a peripheral
vein by three-minute stages of 10, 20, 30 and 40 Pg/kg/min, respectively. The infusion was
stopped when 85% of age-predicted heart rate was reached. Otherwise, dobutamine infusion
was continued and supplemented by 0.25 mg doses of atropine (to a maximal dose of 1 mg).
The stress test was terminated when severe angina, shortness of breath, symptomatic decrease
in systolic blood pressure (>40 mm Hg), arterial hypertension (>240/120 mm Hg), severe
arrhythmias or other serious adverse effects occurred.
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The contrast examination. Sonovue (Bracco, Milan, Italy) was used at baseline conditions,
low-dose and peak stress. The contrast agent was given as a bolus of 0.5 ml with additional
boluses of 0.25 ml when needed. A low mechanical index (0.3) was used. Care was taken to
record the images at a phase when contrast flow was relatively stable with absent or minimal
swirling of contrast in the apex.
Real-time three-dimensional dobutamine stress echocardiography. The RT3DE images
were acquired from an apical window with a Sonos 7500 echo system (Philips Medical
Systems, Best, The Netherlands) equipped with a 3D data acquisition software package. X4
matrix array transducer was attached to the echocardiograph. After visualizing the reference
images (the apical four-chamber and orthogonal views) a full volume data set of the LV was
acquired. With electrocardiographic gating four pyramidal subvolumes of ~20x80° were
acquired during the first, third, fifth, and seventh cardiac cycle. These four conical subvolumes
were automatically integrated into a pyramidal data set of ~80x80° incorporating full LV
volume. Regional LV wall motion was evaluated using cropped planes representative of the 4-
chamber, 2-chamber, and 3-chamber view.
Off-line data analysis: The digitally stored RT3DE data set was analysed off-line with
assistance of 4D TomTec Echo-View 5.3 software (TomTec Inc., Unterschleissheim,
Germany). The RT3DE data set was judged on the basis of the absence of artefacts throughout
the cardiac cycle. All at peak stress available reconstructed segments were graded as optimal
(excellent quality without possibility to improve - 4), good (good quality without artefacts - 3),
moderate (sufficient quality without artefacts or good quality with artefact - 2) or poor (poor or
moderate quality with artefacts - 1). An image quality index was calculated for each segment
by summation of all scores in that particular segment divided by the number of analysed
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segments. Wall motion was assessed using the standard 17-segment LV model of the 3
reconstructed apical views by two independent observers who were blinded to the patient’s
clinical data (7). Wall motion was scored as normal, mild hypokinesia, severe hypokinesia,
akinesia and dyskinesia. A test was considered positive in case of new or worsening wall
motion abnormalities at any stage during stress. Segmental wall motion abnormalities were
assigned to coronary artery territories as described before (1).
Statistical analysis. All values were expressed as a mean ± SD. The Student t test was used to
FRPSDUH WKH GLIIHUHQFHEHWZHHQWHVWV7KHNDSSDț FRHIILFLHQWZDV FDOFXODWHG WRGHWHUPLQH
interobserver agreement. A kappa value <0.4 was considered poor, 0.4 to 0.7 moderate, and
>0.7 good. Data were analyzed using standard statistical software (SPSS, version 12.0,
Chicago, Illinois).
Results
Dobutamine stress data. Heart rate increased from 71 r 13 to 124 r 23 bpm and systolic
blood pressure from 128 r 21 to 140 r 29 mm Hg. No significant side effects were
encountered during the dobutamine stress contrast study.
Myocardial segmental visibility. At peak stress, 466 of the 612 segments (76%) could be
analysed during conventional stress RT3DE. With contrast-enhanced stress RT3DE, the
number of available LV segments increased to 553 (90%). Non-visualized LV segment
distribution during conventional and contrast-enhanced stress RT3DE is depicted in Figure 1.
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Figure 1 Left ventricular 17-segments model showing the percentage of non-visualized
segments during peak stress with conventional (top) and contrast-enhanced (bottom) three-
dimensional echocardiography.
Myocardial segment image quality. The image quality index of the 466 analysable segments
during conventional stress RT3DE was 2.2. With contrast-enhanced stress RT3DE the image
quality index in the 553 analysable segments was 3.1. The quality index distribution of the
visualized segments during conventional and contrast-enhanced stress RT3DE is depicted in
Figure 2.
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Figure 2 Left ventricular 17-segments model showing the segmental quality index in the
visualized segments during peak stress with conventional (top) and contrast-enhanced (bottom)
at peak stress three-dimensional echocardiography.
Interobserver agreement for ischaemia. As seen in Figure 3, with conventional stress
RT3DE the two observers agreed on the diagnosis of myocardial ischaemia in 85 of 108
coronary territories (agreement 79%, N = 0.26). With contrast-enhanced stress RT3DE, the two
observers agreed on the diagnosis of myocardial ischaemia, in 95 of 108 coronary territories
(agreement 88%, N = 0.59). Study agreement on myocardial ischaemia was present in 26 of 36
studies (agreement 72%, N = 0.43) with conventional stress RT3DE, and in 32 of 36 studies
(agreement 89%, N = 0.77) with contrast-enhanced stress RT3DE.
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Figure 3 Interobserver agreement with conventional (left) and contrast-enhanced (right) three-
dimensional stress echocardiography for the diagnosis of myocardial ischemia for all coronary
territories (top) and the overall study result (bottom).
Discussion
The major findings in this study are: [1] a relatively high number of myocardial segments are
poorly visualized with conventional stress RT3DE, [2] contrast-enhanced imaging significantly
decreases the number of poorly visualized myocardial segments and [3] contrast-enhanced
imaging improves interobserver agreement for diagnosis of myocardial ischemia.
Two-dimensional dobutamine stress echocardiography is based on the detection of
stress-induced wall motion abnormalities and is an important clinical tool for the detection of
coronary artery disease (1). For the detection of wall motion abnormalities endocardial border
visualization is essential. However, an important number of patients have suboptimal echo
windows (6). Second harmonic imaging (8,9) and contrast echocardiography (6,10) are known
to enhance LV endocardial visualization during 2-dimensional dobutamine stress
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echocardiography. Because of the trade off between frame rate, image depth and number of
beams, RT3DE image quality is inherently lower compared to two-dimensional imaging.
Therefore, contrast imaging may be expected to play a major role in improvement of RT3DE
image quality.
In our non-selected patients 24% of LV wall segments could not be visualized at
conventional peak stress RT3DE. In particular, anterior wall segments were poorly visualized.
Obviously, this is an important limitation for conventional stress RT3DE because this wall is
crucial for the diagnosis of left anterior descending disease. Apart from an inherently lower
quality of three-dimensional imaging, the large X4 transducer footprint (24x20 mm) may be
responsible for this limitation. As seen in Table 2, our results of conventional RT3DE imaging
look unfavourable compared to other published studies (3-5,11,12). It should, however, be
noticed that we studied non-selected patients whereas in other studies patients with poor two-
dimensional image quality were excluded from analysis (4,11).
Contrast stress RT3DE substantially decreased the number of non-visualized LV
segments and the quality of the visible LV segments was markedly higher. These results
confirm the value of contrast use for stress RT3DE recently published by Pulerwitz et al. in a
very small group of 14 patients (11). Importantly, our study is the first in which it is shown that
the improved visibility of segments at peak RT3DE stress improves interobserver agreement
for the diagnosis of myocardial ischemia in coronary territories with N-values that improved
from poor to moderate and for the overall diagnosis of myocardial ischemia with N-values that
improved from moderate to good. Notwithstanding our promising results on contrast stress
RT3DE new, better transducer technology seems necessary to bring stress RT3DE into clinical
practice.
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Abstract
Background. Recent technical developments have resulted in high-resolution real-time three-
dimensional echocardiography (RT3DE). The purpose of this study was to investigate the
beneficial role of parasternal-acquired images in addition to apical-acquired images during
contrast stress RT3DE.
Methods. The study comprised 30 consecutive patients (52 r 11 years, 18 males) with chest
pain referred for routine stress testing. The contrast RT3DE images were acquired from the
apical and parasternal window with a Sonos 7500 echo system (Philips Medical Systems, Best,
The Netherlands) attached to a X4 matrix array transducer.
Results. From the apical and parasternal acquisition, 464 segments (91%) and 267 segments
(52%) could be analysed, respectively (P <0.001). From the apical window, more basal
segments were not analysable (22 of 180, 12% vs. 24 of 330, 7%; P =0.06). From the
parasternal window, more apical segments were not analysable (117 of 150, 78% vs. 126 of
360, 35%; P <0.01). The mean image quality index of the 464 analysable segments from the
apical-acquired images was 2.43. Fourteen out of 180 basal segments (8%), 12 out of 180 mid-
ventricular segments (7%) and 2 out of 150 apical segment (1%) were only available with
parasternal data acquisition. In addition to these 28 segments, 79 segments (17%) already
visualised from the apical window improved in quality. The overall mean image quality index,
now assessed from 492 (96%) of all segments, using both the apical and parasternal acquired
data, improved to 2.74 (P <0.05).
Conclusions. Addition of parasternal to apical acquisition of contrast RT3DE data can
decrease the number of non-visualised segments and improve mean image quality.
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Introduction
Recent technical developments have resulted in high-resolution real-time three-dimensional
echocardiography (RT3DE) transducers that allow quick acquisition of cardiac images from a
single acoustic window (1). Unfortunately, this technique is still limited by the inherently
lower image quality compared to 2D imaging. It has been shown by others and us that the use
of contrast during stress RT3DE improves image quality and interobserver variability in
identifying wall motion abnormalities (2,3). Despite this improvement stress contrast RT3DE
is still hampered by non-visible left ventricular (LV) segments or segments with suboptimal
image quality, in particular in the anterior (2,3) and lateral wall (2). One of the causes for the
suboptimal image quality of these walls may be the relatively large footprint of the 3D
transducer. Interfering ribs may block echo beams and cause a partially empty 3D data set.
Smaller footprints or acquiring data from a second window, such as the parasternal window,
may eliminate these limitations. The purpose of this study was to investigate the beneficial role
of parasternal-acquired images in addition to the normal apical-acquired images.
Patients and methods
Patient population: The study comprised 30 consecutive patients (52 r 11 years, 18 males) in
sinus rhythm with chest pain referred for routine stress testing. The institutional review board
approved the study and all patients gave informed consent.
The contrast examination: Sonovue (Bracco, Milan, Italy) was used at baseline conditions,
low-dose and peak stress. The contrast agent was given as a bolus of 0.5 ml with additional
boluses of 0.25 ml when needed. A low mechanical index (0.3) was used. Care was taken to
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record the images at a phase when contrast flow was relatively stable with absent or minimal
swirling of contrast in the apex.
Real-time three-dimensional dobutamine stress echocardiography: Dobutamine was
infused according to the standard protocol (4). The RT3DE images were acquired from the
apical and parasternal window with a Sonos 7500 echo system (Philips Medical Systems, Best,
The Netherlands) attached to a X4 matrix array transducer. After visualizing the reference
images (the apical four-chamber and orthogonal views) a full volume data set of the LV was
acquired. With electrocardiographic gating four pyramidal subvolumes of ~20x80° were
acquired during the first, third, fifth, and seventh cardiac cycle. These four conical subvolumes
were automatically integrated into a pyramidal data set of ~80x80° incorporating full LV
volume. In all patients, regional LV wall motion was evaluated using cropped long-axis and
short-axis views at three different levels: above the mitral valve, at the papillary muscle level
and at the apex.
Off-line data analysis: The digitally stored RT3DE data set was analysed off-line with
assistance of QLAB software (Philips, Best, the Netherlands). The RT3DE data set was judged
on the basis of the absence of artefacts throughout the cardiac cycle. All available
reconstructed segments were graded as optimal (excellent quality without possibility to
improve - 4), good (good quality without artefacts - 3), moderate (sufficient quality without
artefacts or good quality with artefact - 2) or poor (poor or moderate quality with artefacts - 1).
An image quality index was calculated for each segment by summation of all scores in that
particular segment divided by the number of analysed segments. The attribution of the different
myocardial segments to the coronary arteries was done according to current guidelines and is
displayed in Figure 1 (5).
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Figure 1. Attribution of the different myocardial segments to the different coronary arteries.
Statistical analysis: All values were expressed as a mean ± SD. The Student t test was used to
compare the difference between tests. Data were analyzed using standard statistical software
(SPSS, version 12.0, Chicago, Illinois).
Results
Myocardial segmental visibility. From the apical and parasternal acquisition, 464 segments
(91%) and 267 segments (52%) could be analysed, respectively (P <0.001). The non-visualized
LV segment distribution during apical and parasternal data acquisition is depicted in Figure 2.
Figure 2. Left ventricular 17-segments model showing the percentage of non-available
segments during apical (top) and parasternal (bottom) data acquisition during real-time three-
dimensional echocardiography.
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With apical-acquired images the percentage of non-analysable segments attributed to the left
anterior descending coronary artery was higher compared to the number of non-analysable
segments attributed to the left circumflex or right coronary artery (27 of 210, 13% vs. 19 of
300, 6%; P <0.02). With parasternal imaging, the percentage of non-analysable segments
attributed to the left anterior descending coronary artery was comparable to the number of non-
analysable segments attributed to the left circumflex or right coronary artery (103 of 210, 49%
vs. 140 of 300, 47%; P = NS). From the apical window, more basal segments were not
analysable (22 of 180, 12% vs. 24 of 330, 7%; P =0.06). From the parasternal window, more
apical segments were not analysable (117 of 150, 78% vs. 126 of 360, 35%; P <0.01).
Myocardial segment image quality. The mean image quality index of the 464 analysable
segments from the apical-acquired images was 2.43. With parasternal data acquisition the
image quality index in the 267 analysable segments was 2.61. The quality index distribution of
the visualized segments during apical and parasternal data acquisition is depicted in Figure 3.
Figure 3. Left ventricular 17-segments model showing the segmental quality index in the
visualized segments during apical (top) and parasternal (bottom) data acquisition during real-
time three-dimensional echocardiography.
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In the analysable segments from the apical window mean quality index was lowest for the
basal segments (2.12 basal vs. 2.64 mid and 2.51 apical, all P <0.001, respectively). In the
analysable segments from the parasternal window mean quality index was lowest for the apical
segments (2.09 apical vs. 2.38 mid, p = 0.07, 2.09 apical vs. 2.66 basal, P <0.01).
Additive value of parasternal acquisition. Fourteen out of 180 basal segments (8%), 12 out
of 180 mid-ventricular segments (7%) and 2 out of 150 apical segment (1%) were only
available with parasternal data acquisition. The distribution of these segments and their mean
quality indices are depicted in Figure 4.
Figure 4. Quality index (top) and segment number (bottom) visible uniquely during parasternal
data acquisition.
Mean quality index in these 28 segments was 2.93. In addition to these 28 segments, 79
segments (17%) already visualised from the apical window improved in quality. The overall
mean image quality index, now assessed from 492 (96%) of all segments, using both the apical
and parasternal acquired data, improved to 2.74 (P <0.05).
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Discussion
The major findings in this study are: [1] a substantial number of LV myocardial segments are
not visualized during apical-acquired contrast-enhanced stress RT3DE, and [2] addition of
parasternal acquisition of RT3DE data can decrease the number of non-visualised segments
and improve mean image quality.
Stress echocardiography relies on regional, rather than global, assessment of LV
function. Therefore, visibility of as many as possible LV segments at the highest available
quality is mandatory. Previously, others and us have shown the value of ultrasound contrast
during stress RT3DE to maximize the for analysis available segments and improve image
quality (2,3,6). Unfortunately, still a significant number of segments are not visualised during
the standard apical acquisition and the image quality is suboptimal. This seems primarily
related to the relatively large footprint of the 3D transducer and inherently lower quality of 3D
imaging, because of the trade off between frame rate, number of beams, and depth. In addition,
the differentiation between contrast and tissue is not as good as in standard 2D harmonic
imaging, because the matrix transducer with its limited relative bandwidth is less suitable for
harmonic imaging. Additional parasternal data acquisition may offer some advantages. In
particular basal segments are known to be imaged suboptimal from the apical window during
contrast RT3DE (3,7), whereas these segments are usually the better ones imaged from the
parasternal window. In addition, some walls may be better imaged from a parasternal window
because of axial rather than lateral resolution.
In our study 9% of all LV segments acquired from the apical window could not be
obtained. This number is comparable to the results of Zwas et al. who reported that 11% of LV
segments acquired from the apical window could not be obtained during treadmill stress 3D
echocardiography (8). In particular basal segments and/or segments assigned to the left anterior
descending coronary artery were less visualised, confirming previous reports (2,3,7). From the
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parasternal window significantly less segments could be visualised. However, 28 segments
(5%) could be visualised uniquely from the parasternal-acquired data set with a high image
quality index. In particular, a substantial number of basal segments and/or segments assigned
to the left anterior descending coronary artery could be visualised only from the parasternal-
acquired data set. The total number of visualised segments increased from 464 (91%) from the
apical window to 492 (96%) from the apical combined with parasternal window with
corresponding mean image quality indices of 2.43 and 2.74, respectively. Unfortunately, this
multi-window approach eliminates one of the advantages of stress RT3DE, the rapid
acquisition from one single acoustic window. Therefore, future studies should look to the
availability and quality of segments acquired from only the apical window with the new,
smaller X3-1 matrix transducer and re-assess the necessity of the addition of a second window.
Conclusion
Stress echocardiography depends on regional wall motion analysis. With contrast stress
RT3DE inclusion of both apical and parasternal acquired images in the data set is essential to
increase the number of visualized segments and to improve overall image quality.
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Abstract
Dobutamine stress magnetic resonance imaging is considered the superior stress modality to
detect wall motion abnormalities. In this report we demonstrate the strengths of a newly
developed stress modality: dobutamine stress contrast-enhanced real-time three-dimensional
echocardiography. This stress modality may become a competitor for stress magnetic
resonance imaging allowing fast acquisition and an unlimited number of left ventricular cross-
sections. Unfortunately, at this moment adequate imaging with stress real-time three-
dimensional echocardiography is only possible in the minority of cardiac patients.
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Introduction
Two-dimensional stress echocardiography (DSE) has become a well-established stress
modality for the detection of coronary artery disease (CAD) (1). However, the number of left
ventricular cross sections and in particular variable image quality may limit this imaging
modality. Magnetic resonance imaging (MRI) overcomes these limitations and in stress MRI
studies superior results with respect to the diagnosis of CAD were reported (2). More recently,
the diagnostic accuracy of DSE has been improved by new developments such as second
harmonic imaging (3), contrast imaging (4) and three-dimensional imaging (5). The optimal
DSE test may include the use of all these new techniques in combination. In this case report we
show the imaging potentials of dobutamine stress real-time three-dimensional contrast-
enhanced echocardiography (RT3DE), simulating a stress MRI study with respect to unlimited
left ventricular cross sections and image quality.
Case study
A 65 year-old-woman was admitted to our outpatient clinic for pre-operative risk stratification
(infected knee prosthesis). Since several years she experienced stable angina. Risk factors for
coronary artery disease were negative. Because of her complains and orthopedic problems (that
precluded an exercise test) dobutamine stress MRI was performed. During dobutamine stress
(40 Pg/kg/min) the heart rate increased from 75 to 125 bpm (target heart rate was 115 bpm)
and blood pressure increased from 120/75 to 125/65 mm Hg. The patient did not experience
angina nor were electrocardiographic signs of myocardial ischemia seen. Routine 4-chamber,
2-chamber and 3-chamber views and basal, mid and apical short axes were recorded at rest,
low-dose and peak stress. To show the capabilities of stress RT3DE, this study was performed
several weeks apart from the stress MRI study with a Sonos 7500 ultrasound system (Philips,
Best, The Netherlands) attached to a phased-array scanner and repeated SonoVue boluses of
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0.5 ml. During stress RT3DE similar hemodynamic data were achieved (stress heart rate 123
bpm). As seen in Figures 1-2, identical left ventricular cross sections (short-axis views at basal,
mid and apical level and long-axis views) could be cropped out of the thee-dimensional data
set.
Figures 1 and 2 Identical left ventricular cross sections (short-axis views at basal, mid and
apical level) and apical 4-chamber views by stress MRI and RT3DSE with and without LVO
Discussion
During stress RT3DE it takes only 7 cardiac cycles (3 to 5 seconds at peak stress) to record a
full three-dimensional data set. Subsequently, an unlimited number of left ventricular cross-
sections can be cropped out of this data set. Contrast-enhanced images have been shown to
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improve left ventricular endocardial border detection and to increase the diagnostic accuracy of
conventional DSE (4). In our experience echo contrast is mandatory in most stress RT3DE
studies because image quality is somewhat lower compared to conventional two-dimensional
imaging (because of lower resolution and frame rate) (6). Eventually, contrast-enhanced stress
RT3DE may become a competitor for stress MRI allowing fast acquisition and an unlimited
number of left ventricular cross-sections. However, at this moment adequate imaging with
stress RT3DE is only possible in the minority of cardiac patients. Although stress MRI may be
limited by local availability and not all patients can undergo this test due to claustrophobia (in
approximately 5% of patients) or contraindications such as non-compatible biometallic
implants and pacemakers or implanted cardiac defibrillators, stress MRI should be considered
the gold standard test to induce and visualize myocardial ischaemia (7,8). Stress MRI is well
suited for overcoming the limitations of DSE. It has no acoustic window limitations and thus
can comprehensively visualize the left ventricular myocardium regardless of body habitus.
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Abstract
Background. Pompe's disease, also known as acid maltase deficiency or glycogen storage
disease type II, is an autosomal recessive disorder in which deficient activity of the enzyme
acid Į-glucosidase causes intra-lysosomal accumulation of glycogen in muscle and other
tissues. The current study was designed to assess aortic stiffness index (ȕ), as a characteristic
of aortic elasticity during transthoracic echocardiography in patients with Pompe`s disease.
Methods. A total of 17 patients (age 44 ± 8 years, 5 males) with Pompe`s disease were studied.
Their results were compared to 17 age- and gender-matched controls. In all patients, the
ascending aorta was recorded with M-mode echocardiography. ȕ was calculated as
ln(SBP/DBP)/[(SD-DD)/DD], where SBP and DBP are the systolic and diastolic blood
pressures, SD and DD are the systolic and diastolic aortic diameters, and ’ln’ is the natural
logarithm.
Results. Diastolic aortic diameter was 27.4 ± 2.4 mm in Pompe patients and 25.6 ± 2.7 mm in
controls (P <0.05). Systolic aortic diameters did not differ between the groups (29.4 ± 2.5 mm
vs 28.3 ± 2.4 mm, P=ns). Aortic stiffness index (ȕ) was increased in Pompe patients compared
to controls (14.6 ± 10.1 vs 5.1 ± 2.6, P <0.001).
Conclusions. The results of this study indicate that aortic stiffness is increased in patients with
Pompe`s diasease. This may be due to glycogen storage in the vessel wall causing reduced
vascular elasticity.
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Introduction
Pompe's disease, also known as acid maltase deficiency or glycogen storage disease type 2, is
an autosomal recessive disorder in which deficient activity of the enzyme acid Į-glucosidase
causes intra-lysosomal accumulation of glycogen in muscle and other tissues (1). Muscle
weakness is the most important clinical symptom, but the effect of Pompe`s disease on human
aortic compliance is not well established (2). The manifestation and physiologic implications
of aortic pulsatility are of considerable interest, because it provides useful information
regarding aortic vasomotion function. Ascending aortic diameter changes during the heart
cycle can be reliably measured with two-dimensional transthoracic echocardiography. For
characterisation of aortic elasticity, aortic stiffness index (ȕ) can be used (3). The current study
was designed to assess ascending aortic elastic properties in patients with Pompe`s disease and
to compare these results to age- and gender-matched controls.
Materials and methods
Study population. A total of 17 patients with typical features of adult-onset Pompe`s disease
(44 ± 8 years, 5 males) without cardiovascular risk factors (diabetes mellitus, hypertension,
smoking, hypercholesterolaemia) were investigated. Pompe diagnosis was based on clinical
symptoms (exercise intolerance due to skeletal muscle problem) caused by partial deficiency
of acid Į-glucosidase activity. Their results were compared to 17 age- and gender-matched
controls without cardiovascular risk factors. None of the patients or control subjects received
therapeutic drugs. Informed consent was obtained from each patient and the study was
approved by the institutional review board.
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Blood pressure measurement. Systolic and diastolic blood pressures (SBP and DBP,
respectively) were measured in the supine position with an automatic mercury cuff
sphygmomanometer from the left arm after 10 min of rest. None of the patients or control
subjects used coffee or tea within one hour before blood pressure measurements and by
exclusion none of the patients or control subjects were smoker.
Transthoracic echocardiography. All subjects underwent a complete two-dimensional
transthoracic echocardiography and Doppler study using a Philips Sonos 7500
echocardiography equipment (Philips, Best, The Netherlands) in the left lateral decubitus
position from multiple windows. Systolic and diastolic ascending aortic diameters (SD and
DD, respectively) were recorded in M-mode at a level of 3 cm above the aortic valve from a
parasternal long-axis view (Figure 1). The SD and DD were measured at the time out of
maximum aortic anterior motion and at the peak of QRS complex, respectively. Aortic stiffness
index (�) was defined as ln(SBP/DBP)/[(SD-DD)/DD], where ’ln’ is the natural logarithm.
Figure 1 Measurements of systolic (SD) and diastolic (DD) diameters of the ascending aorta
are shown on the M-mode tracing obtained at a level 3 cm above the aortic valve.
127
Statistical analysis. All data are reported as mean r standard deviation. For comparing
variables, the student t test was used (SPSS 12.0 software). A value of p<0.05 was considered
statistically significant.
Reproducibility of echocardiographic measurements. The reproducibility of the aortic
diameter measurements was assessed in all 17 Pompe patients at both systole and diastole by
two independent, blinded observers. Agreement between the two observers was verified using
the Bland-Altman method (4).
Results
Transthoracic echocardiography. All patients had normal left atrial and left ventricular
dimensions and function. Mean diastolic aortic diameter was larger and mean aortic stiffness
index (ȕ) was significantly increased in Pompe`s disease patients compared to controls (Table
1). Individual ȕ indices of Pompe patients and control subjects are presented in Figure 2.
Figure 2 Individual ȕ indices of Pompe patients and control subjects
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Table 1 Echocardiographic and blood pressure data in Pompe patients and normal
subjects
Group 1
(normal subjects)
Group 2
(Pompe`s disease)
Body mass index (kg/m2) 30.3 ± 5.7 23.9 ± 2.7 #
LV end-diastolic diameter (mm) 49.5 ± 6.7 48.1 ± 3.9
LV end-systolic diameter (mm) 31.1 ± 8.5 31.3 ± 4.8
LV ejection fraction (%) 68.9 ± 7.7 69.7 ± 6.9
Systolic aortic diameter (mm) 28.3 ± 2.4 29.4 ± 2.5
Diastolic aortic diameter (mm) 25.6 ± 2.7 27.4 ± 2.4 *
Pulsatile change in aortic diameter (mm) 2.9 ± 1.3 2.0 ± 2.0
Systolic blood pressure (mm Hg) 132.6 ± 9.4 134.2 ± 15.4
Diastolic blood pressure (mm Hg) 83.5 ± 8.6 80.5 ± 9.8
Aortic pulse pressure (mm Hg) 49.1 ± 9.6 53.6 ± 12.1
Aortic stiffness index (ȕ) 5.1 ± 2.6 14.6 ± 10.1 #
Continuous variables are given as mean ± standard deviation * = P <0.05. # = P <0.001.
LV = left ventricular.
Reproducibility. The mean ± SD difference in values obtained by two observers for the
measurements of systolic aortic diameter was 0.7 ± 1.2 mm, with a correlation coefficient
between these independent measurements of 0.84 (P <0.001). At diastole, the difference
between these observations was 0.2 ± 1.4 mm, with a correlation coefficient between
observations of 0.88 (P <0.001). The interobserver difference in values was within twofold of
the standard deviation of the mean (Figure 3).
129
Figure 3 Interobserver correlations and reproducibility measurements between systolic and
diastolic aortic diameters in Pompe`s patients.
Discussion
Pompe`s disease is an autosomal recessive lysosomal storage disorder, caused by acid Į-
glucosidase deficiency (5). To the best of the authors` knowledge, the elastic properties of the
aorta have never been reported in Pompe patients. Greater diastolic aortic diameters with
smaller pulsatile aortic diameter changes related to aortic remodelling resulted in increased ȕ
values in Pompe patients.
Increased arterial stiffness is an independent risk factor and predictor of cardiovascular
mortality in a variety of diseases (6). Direct measurement of arterial stiffness requires invasive
techniques unsuitable for routine clinical practice (3). In the present study, the aortic elastic
parameters were derived from the pulsatile change in ascending aortic diameter and
conventional left brachial arterial systolic and diastolic blood pressures. Aortic stiffness index
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(ȕ), a characteristic of aortic elasticity, represents the slope of the exponential function relating
the relative arterial pressure and the distention ratio of the artery and characterizes the entire
deformation behavior of the vascular wall. This non-invasive ȕ index has been confirmed as a
determinant of aortic distensibility, with a high degree of accuracy in comparison with invasive
methods (3).
In recent morphological studies in Pompe patients glycogen storage has been
demonstrated in smooth muscle cells of the arteries and veins (7). With disease progression,
the integrity of the blood vessel wall may become lost, which can explain the occurrence of
aneurysms in the basal arteries in Pompe`s disease (7,8). It can only be hypothesized that
glycogen storage is responsible for the increased aortic stiffness in our study. Other factors
known to be associated with aortic stiffness such as diabetes mellitus, hypertension, smoking
or hypercholesterolaemia were excluded in our patients. At this moment, Į-glucosidase enzyme
replacement therapy is under investigation in the multicenter LOTS (Late Onset Therapy
Study) trial. If aortic stiffness will improve with enzyme replacement therapy, this may
confirm the potential role of glycogen storage in the development of increased aortic stiffness.
The most important limitation is that noninvasive brachial cuff pressure measurement instead
of a direct assessment of blood pressure by a catheter was used. However, others have shown
excellent correlation in the evaluation of aortic distensibility using invasive and noninvasive
methods (3).
Conclusions. Aortic elastic properties are altered and aortic distensibility is decreased in
patients with Pompe`s disease. These alterations may be due to glycogen storage in the aortic
wall. Potential reversal of aortic distensibility should be tested in ongoing enzyme replacement
therapy trials.
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Abstract
Objective. Mucopolysaccharidosis type I (MPS IS) is a rare autosomal recessive disease
caused by a deficiency of the lysosomal enzyme D-L-iduronidase, which is involved in the
degradation of sulfated glycosaminoglycans (GAGs). The deficiency results in the intra- and
pericellular accumulation of the GAGs heparin sulfate and dermatan sulfate.
Methods. Eight adult patients with typical features of MPS IS were included and compared to
age and gender-matched controls. With transthoracic echocardiography, cyclic ascending aortic
diameter changes and the aortic stiffness index was measured to characterize aortic elasticity.
Results. In MPS IS patients, systolic and diastolic aortic diameters and mean aortic stiffness
index were significantly increased compared to age and sex matched controls.
Conclusions. The results of the present study demonstrate that in addition to the known
cardiac complications, MPS IS patients have an impairment of aortic elasticity. Further follow-
up studies are needed to examine arterial elasticity using other methods in this patient
population, and to detect possible effects of enzyme replacement therapy.
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Introduction
Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disease caused by
deficiency of the lysosomal enzyme D-L-iduronidase. This enzyme is involved in the
degradation of sulfated glycosaminoglycans (GAG)s and deficiency results in intracellular and
pericellular accumulations of the GAGs heparin sulfate and dermatan sulphate (1). Deficiency
of D-L-iduronidase gives rise to three main clinical entities – Hurler syndrome (MPS IH),
presenting in infancy and the most severe phenotype, Hurler-Scheie syndrome (MPS IH/S), a
phenotype presenting in childhood and of intermediate severity, and Scheie syndrome (MPS
IS), the mildest form of MPS I. Cardiomyopathy and thickening of cardiac valves and large
vessels have been described in MPS I patients, especially in MPS IH (2,3). Autopsy studies
have described aortic GAG accumulations in MPS IH patients. GAG accumulation in the aorta
could conceivably affect aortic wall function and contribute to further decay in cardiac function
(4). With transthoracic echocardiography, cyclic ascending aortic diameter changes and the
aortic stiffness index (ȕ) can be measured to characterize aortic elasticity (5). The current study
was designed to assess ascending aortic stiffness in adult patients with the less severe MPS IS
phenotype.
Materials and methods
Eight adult patients with typical features of MPS IS aged 30 ± 6 years (five men) were
included (Table 1). The diagnosis of MPS I was based on demonstrating a deficiency of D-L-
iduronidase activity in cultured fibroblasts. The results of the ultrasound studies were compared
to 20 age- and gender-matched healthy controls. Informed consent was obtained from each
patient and the study was approved by the institutional review board. In all patients blood
pressure was measured in the supine position with a mercury sphygmomanometer. None of the
patients or control subjects received therapeutic drugs, used coffee or tea within one hour
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before blood pressure measurements or was a smoker. All subjects underwent a complete 2-
dimensional transthoracic echocardiographic and Doppler study using a Philips Sonos 7500
system (Philips, Best, The Netherlands) in the left lateral decubitus position from multiple
windows. Systolic and diastolic ascending aortic diameters (SD and DD, respectively) were
recorded in M-mode at a level 3 cm above the aortic valve from a parasternal long-axis view,
according to a method described previously in more detail (5,6). SD and DD were measured at
the time of maximum aortic anterior motion and at the peak of the QRS complex, respectively.
The aortic stiffness index was calculated from the echocardiographically derived aortic
diameters and the clinical blood pressure by using the following formula ln(SBP/DBP)/[(SD-
DD)/DD], where ’ln’ is the natural logarithm. All data are reported as mean r standard
deviation. For comparing variables, the student t test was used (SPSS 12.0 software). A value
of p<0.05 was considered to be statistically significant. Interobserver reproducibility for
measuring systolic and diastolic aortic diameters in our institution is 84 and 88%, respectively
(7).
Results
Clinical and demographic data of MPS IS patients and controls are presented in Table 1.
Systolic and diastolic aortic diameters of MPS IS patients were significantly increased. Mean
aortic stiffness index (ȕ) was significantly increased in MPS I patients compared to controls
(Figure 1).
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Table 1 Echocardiographic and blood pressure data in MPS I patients and normal
subjects
Group 1
(normal subjects)
Group 2
(patients with MPS I)
LV end-diastolic diameter (mm) 46.6 ± 4.6 47.3 ± 3.5
LV end-systolic diameter (mm) 28.1 ± 2.8 31.4 ± 4.0#
LV ejection fraction (%) 70.9 ± 5.9 64.9 ± 4.6#
Systolic aortic diameter (mm) 25.7 ± 2.7 28.1 ± 3.3#
Diastolic aortic diameter (mm) 22.4 ± 2.6 27.4 ± 3.2*
Pulsatile change in aortic diameter (mm) 3.3 ± 1.2 0.8 ± 0.4*
Systolic blood pressure (mm Hg) 129.6 ± 24.2 115.3 ± 20.7
Diastolic blood pressure (mm Hg) 77.3 ± 13.2 67.3 ± 9.8
Aortic pulse pressure (mm Hg) 52.3 ± 16.2 48.0 ± 14.6
Aortic stiffness index (ȕ) 3.9 ± 1.5 23.1 ± 10.4*
Continuous variables are given as mean ± standard deviation * P <0.001. # P<0.05
LV = left ventricular.
Figure 1 Individual ȕ indices of MPS I patients and control subjects
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Discussion
To the best of the authors’ knowledge this is the first time that alterations in aortic elasticity are
investigated by a non-invasive echocardiographic method in adult patients with MPS IS.
Direct measurement of arterial stiffness requires invasive techniques unsuitable for routine
clinical practice. Stefanadis et al. have demonstrated that the non-invasively evaluated ȕ index
as a determinant of aortic distensibility is comparable with invasive methods with a high
degree of accuracy (5).
Increased aortic stiffness in MPS IS patients was found as compared to age- and
gender-matched healthy controls. MPS I is a rare disease in which a deficiency of the
lysosomal enzyme D-L-iduronidase results in accumulation of heparan sulfate and dermatan
sulfate within the central nervous system, lungs, liver, bones, cartilage and heart. The disorder
is clinically heterogeneous, the clinical spectrum ranging from the very severe Hurler
syndrome to the attenuated Scheie syndrome, with a diverse group of intermediate severity
known as Hurler-Scheie.
Within the heart, GAG accumulation is associated with thickened cardiac valves,
progressive narrowing and occlusion of the epicardial coronary arteries, and congestive heart
failure. A variety of vessels can b e involved showing various facets of the arteriopathy in
MPS I. The assessment of coronary artery involvement in MPS I is difficult. Because of its
diffuse nature, routine coronary angiography fails to identify severe myointimal proliferation
(8). Irregular narrowing of the abdominal aorta with either multiple asymmetric wall lesions or
abrupt concentric narrowing has been found to be present in some children by different
imaging methods (aortography, sonography or magnetic resonance imaging) (9). In accordance
with a recently published study, the aorta in our MPS I patients was dilated suggesting
remodeling of this vessel (2). In addition to these changes in aortic dimensions, elastic
properties were also changed and may also be due to GAG storage in the aortic wall. In MPS
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IH, the accumulation of dermatan sulfate has been shown to impair the formation of normal
elastin fibres by inactivating the chaperone involved, elastin-binding protein (10,11). Apart
from the abnormal elastin structure, changes in collagen formation and collagen cross-linking
have been described in other tissues such as skin and cornea. Such changes in collagen could
contribute to the functional changes in the aorta and other blood vessels (12,13).
Enzyme replacement therapy with recombinant human Į-L-iduronidase (laronidase,
Aldurazyme, BioMarin Pharmaceutical Inc., Novato, California, and Genzyme Corporation,
Cambridge, Massachusetts) has recently been approved for use in children with MPS I (14).
Preliminary results by Braunlin et al. suggest that long-term enzyme replacement therapy is
beneficial for the myocardium, but the cardiac valves appeared unresponsive. Unfortunately,
effects on blood vessels was not studied (3).
In conclusion, this study provides evidence that aortic involvement, which has
previously only been described in post mortem studies in severe form MPS IH, also occurs in
the milder forms of MPS I, like MPS IS. The measurement of aortic stiffness by a non-invasive
means provides a way to follow progression of disease and the effect of new treatment options.
The potential reversibility of this impaired aortic distensibility should be examined in ongoing
enzyme replacement therapy trials.
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Abstract
Background. Aortic valve stenosis (AS) is the most frequent form of valvular heart disease.
The number of studies evaluating the effect of aortic valve replacement (AVR) for AS on
aortic vascular function is limited. The aim of the present study was to examine alterations in
aortic distensibility in AS patients during a one-year follow-up after AVR.
Methods. Twelve patients with severe AS who underwent AVR were prospectively
investigated (mean age 65 ± 11 years, 7 males). Systolic and diastolic ascending aortic
diameters (SD and DD, respectively) were recorded in M-mode 3 cm above the aortic valve
from a parasternal long-axis view. The SD and DD were measured at the time of maximum
anterior motion of the aorta and at the start of the QRS complex, respectively. Aortic stiffness
index (ȕ) was defined as [ln(SBP/DBP)]×DD/ǻ'ZKHUH¶OQ¶LVWKHQDWXUDOORJDULWKP6%3DQG
'%3DUHWKHV\VWROLFDQGGLDVWROLFEORRGSUHVVXUHYDOXHVDQGǻ' 6'–DD.
Results. As expected, aortic stenosis severity and left ventricular mass decreased significantly
after AVR. Aortic diameter changes (systolic minus diastolic dimensions) progressively
increased, and the aortic stiffness index progressively improved to levels comparable to age,
gender and risk factor-matched controls at the one year assessment.
Conclusions. AVR in AS patients is associated with a progressive improvement in aortic
distensibility to one year values similar to age, gender and risk factor-matched controls.
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Introduction
Aortic valve stenosis (AS) is the most frequent form of valvular heart disease. Impaired
coronary microcirculation and decreased coronary flow reserve (CFR) are well-known
alterations associated with AS regardless of the presence or absence of coronary artery disease
(CAD) (1) In recent studies, improvement in CFR has been described within one-year after
AVR (2,3). Impaired aortic elastic properties have also been demonstrated in AS patients (4,5).
This finding supported the suggestion that decreased aortic distensibility in valvular AS can be
an early manifestation of the atherosclerotic process (endothelial dysfunction), decreased
perfusion of the aorta or other factors beyond physical pressure effects (4). Unfortunately,
long-term data on changes in aortic elasticity after AVR are not yet available. The aim of the
present study was to examine alterations in aortic distensibility in AS patients during an one-
year follow-up after AVR.
Methods
Study population. Twelve patients with severe AS who underwent AVR were prospectively
investigated (mean age 65 ± 11 years, 7 males). Risk factors for cardiovascular disease
included hypertension in two and diabetes in one. AVR was carried on in all patients, four
patients with coronary artery disease underwent additional coronary artery bypass grafting. All
results were compared to 12 age-, gender- and risk factor-matched controls. All patients
underwent transthoracic two-dimensional echocardiography before and 3-weeks, 6-months and
12-months after AVR. Informed consent was obtained from each patient and the study was
approved by the hospital`s medical ethical committee and complied with the Declaration of
Helsinki.
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Blood pressure measurement. Systolic and diastolic blood pressures (SBP and DBP,
respectively) were measured in the supine position with an automatic mercury cuff
sphygmomanometer from the left arm after 10 min of rest. Regarding to the European
Guidelines for the Management of Hypertension (2003) blood pressure values were used as
reference phase I (appearance of a tone) and phase V (disappearance) of Korotkoff sounds to
identify SBP and DBP, respectively (6). Blood pressure values were averaged from three
consecutive measurements. None of the patients used coffee or tea within one hour before
blood pressure measurements.
Transthoracic echocardiography. All patients underwent a complete two-dimensional
echocardiography and Doppler study using a Philips Sonos 7500 system (Philips, Best, The
Netherlands) in the left lateral decubitus position from multiple windows. Systolic and diastolic
ascending aortic diameters (SD and DD, respectively) were recorded in M-mode at a level of 3
cm above the aortic valve from a parasternal long-axis view (Figure 1).
Figure 1 Measurements of systolic (SD) and diastolic (DD) diameters of the ascending aorta
are shown on the M-mode tracing obtained at a level 3 cm above the aortic valve.
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Gain, depth, and sector angles were individualized for the best measurement. The SD and DD
were measured at the time of maximum anterior motion of the aorta and at the start of the QRS
complex, respectively. Aortic stiffness index (ȕ) was defined as [ln(SBP/DBP)]×DD/'D,
where ’ln’ is the natural logarithm and 'D = SD – DD (7).
Statistical analysis. Data are reported as means r standard deviation. For comparison between
variables, analysis of variance (ANOVA) test with Bonferroni adjustment was used. A value of
p <0.05 was considered statistically significant. SPSS 12.0 software was used for statistical
calculations. The reproducibility of the aortic diameter measurements was tested in all AS
patients at both systole and diastole by two blinded observers. Agreement between the two
observers was verified using the Bland-Altman method (8).
Results
Cardiovascular changes after AVR. All echocardiographic, haemodynamic and aortic data
are presented in the Table. Post-AVR a significant and sustained decrease was found in peak
and mean aortic gradients. Left ventricular mass progressively decreased, aortic diameter
changes (systolic minus diastolic dimensions) progressively increased, and the aortic stiffness
index progressively improved to levels comparable to age, gender and risk factor-matched
controls at the one year assessment.
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Table 1. Clinical and echocardiographic characteristics of the study population
Controls Before AVR
3 weeks
after AVR
6 months
after AVR
12 months
after AVR
Echocardiographic data
End-diastolic LV diameter (mm) 50.6 ± 4.2&$ 50.3 ± 16.4 44.9 ± 5.9 44.2 ± 3.6 45.1 ± 5.5
End-systolic LV diameter (mm) 32.0 ± 4.0 30.0 ± 6.8 28.4 ± 9.5 27.8 ± 3.5 29.0 ± 4.9
Interventricular thickness (mm) 10.3 ± 1.1*& 15.0 ± 4.6 14.1 ± 3.6 13.4 ± 2.4 13.1 ± 3.3
Posterior wall thickness (mm) 9.8 ± 1.0*& 13.7 ± 3.9 12.8 ± 2.2 11.5 ± 1.8 12.0 ± 3.5
Left ventricular mass (g) 234 ± 45 397 ± 288 284 ± 100 241 ± 58 229 ± 129
Peak aortic gradient (mm Hg) - 90.5 ± 24.3 18.5 ± 7.3* 15.0 ± 4.5* 18.7 ± 5.1*
Mean aortic gradient (mm Hg) - 53.3 ± 12.9 9.3 ± 4.5* 8.4 ± 2.4* 9.3 ± 2.5*
Hemodynamic data
Systolic BP (mm Hg) 149.8 ± 15.0& 144.3 ± 20.7 122.1 ± 10.3 135.8 ± 14.6 132.5 ± 22.1
Diastolic BP (mm Hg) 87.4 ± 8.8& 78.9 ± 9.5 73.3 ± 7.5 77.1 ± 6.6 77.5 ± 11.2
Pulse pressure (mm Hg) 62.4 ± 10.6& 65.3 ± 15.7 48.8 ± 10.5 58.8 ± 10.3 55.0 ± 13.3
Ascending aortic data
Aortic SD (mm) 30.6 ± 3.8 30.7 ± 4.7 29.4 ± 2.9 31.0 ± 3.3 31.0 ± 4.2
Aortic DD (mm) 27.9 ± 3.0 29.6 ± 4.6 28.3 ± 2.9 29.3 ± 3.2 29.0 ± 4.1
Aortic SD - DD (mm) 2.3 ± 1.1*& 1.1 ± 0.5 1.1 ± 0.6 1.7 ± 0.9 2.1 ± 0.8*
Aortic stiffness index (ȕ) 8.2 ± 4.5*& 19.6 ± 10.8 16.7 ± 7.5 12.5 ± 7.1 8.4 ± 3.5*
Variables are expressed as means ± standard deviation. Abbreviation: BP, blood pressure; LV, left ventricle; DD,
diastolic diameter; SD, systolic diameter.
* = P <0.05 compared to before AVR. & = P <0.05 compared to 3 weeks after AVR. $ = P <0.05 compared to 6
months after AVR.
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Figure 2 Aortic stiffness index and pulsatile change in aortic diameter during follow-up
Reproducibility. The mean ± standard deviation difference in values obtained by two
observers for the measurements of aortic diameter at systole was –0.4 ± 1.7 mm, with a
correlation coefficient between these independent measurements of 0.91 (p <0.001) (Figures
3A and 4A). At diastole, the difference between these observations was – 0.02 ± 1.6 mm, with
a correlation coefficient between observations of 0.91 (p <0.001) (Figures 3B and 4B).
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Figure 3A/B and 4A/B Interobserver correlation (r = 0.91, p <0.001 for systolic and (r = 0.91,
p <0.001 for diastolic aortic diameters) and reproducibility of systolic and diastolic aortic
measurements.
Discussion
The number of studies evaluating the effect of AVR for AS on aortic vascular function is
limited. To the best of the authors knowledge this is the first study that examined aortic
elasticity changes up to one year after AVR. In prior studies it has been shown that pulsatile
changes in ascending aortic diameter can be measured during routine transthoracic
echocardiography. Stefanadis et al. described that noninvasive measurements of aortic
distensibility by echocardiography, based on aortic dimensions and blood pressure data, are as
accurate as invasive methods (9). In the present study, aortic stiffness index (ȕ) continued to
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Figure 3A Interobserver correlation between systolic aortic diameter
r = 0.91, p < 0.001
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Figure 3B Interobserver correlation between diastolic aortic diameter
r = 0.91, r < 0.001
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Figure 4B Reproducibility of diastolic aortic measurements
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Figure 4A Reproducibility of systolic aortic measurements
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decrease up to one year after AVR corresponding to improved aortic elasticity to a level
comparable to age, gender and risk factor-matched controls.
There are a limited number of studies evaluating vascular alterations in AS. In most of
them, mainly the coronary microcirculation was examined (1-4,10,11). Reduced coronary flow
reserve (CFR) has been demonstrated in AS patients regardless the presence or absence of
coronary artery disease (CAD) (1-4,10,11). Improvement in CFR within one year after AVR
for AS was described by different groups. This improvement paralleled the reduction in left
ventricular hypertrophy (2).
In a previous study, we reported increased aortic stiffness in AS patients without CAD to
a level comparable to that found in CAD patients without valvular heart disease (4). This
underscores the hypothesis that aortic vascular alterations in AS are caused by multiple factors.
Barbetseas et al. described that AVR with a mechanical valve resulted in a significant decrease
in aortic distensibility one week after AVR (5). However, this was a transient effect, since 6
months post-operatively aortic function ameliorated. The authors explained their findings by
AVR-induced transient trauma to the arterial wall, so called `aortic root stunning` (5). In our
study, this claimed transient early period of `aortic root stunning` may have been missed
because our first post-AVR assessment was done not earlier than three weeks after AVR. We
demonstrated a progressive improvement in aortic stiffness index to levels comparable to age,
gender and risk factor-matched controls at the one-year assessment. Turbulent flow across the
stenotic aortic valve may damage aortic root endothelium. One of the possible explanations for
improvement in vascular elasticity may be recovery of damaged aortic root endothelium, which
has an important role in the production of vasorelaxant factors (12). However, pressure
changes in the proximal aorta also may have played a role in this improvement.
Some studies evaluated changes in vascular function after aortic root replacement.
Schmidtke et al. investigated the influence of different Ross procedure techniques on
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distensibility of the aortic root (13). They found that the freestanding root, inclusion and
subcoronary techniques resulted in comparable hemodynamics, root size and distensibility.
Rajappan et al. demonstrated that up to one year after aortic root replacement, the wall of both
the allogenic and xenogenic root retained near-normal distensibility (14). They were the first to
describe a correlation between elastic properties of the aortic root and left ventricular mass.
Conclusions. AVR in AS patients is associated with progressive improvement in aortic
distensibility to one year values similar to age, gender and risk factor-matched controls.
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Abstract
Aortic stiffness is an important predictor of cardiovascular morbidity and mortality. Non-
invasive measurement of aortic stiffness is a promising challenge for echocardiography. The
most important limitation of previous studies was that regional differences for aortic stiffness
were not taken into consideration. In our patient, we demonstrated the usefulness of real-time
three-dimensional echocardiography in assessment of regional aortic stiffness.
Introduction
Stiffness of large arteries is an important predictor of cardiovascular morbidity and mortality
(1). Two-dimensional transthoracic (TTE) and transoesophageal echocardiography (TEE) are
both useful methods for the evaluation of stiffness in different aortic regions calculated from
aortic and blood pressure data (2-5). Drozdz et al. demonstrated that three-dimensional TEE
has a strong potential for regional aortic stiffness measurements using horizontal cross-
sectional imaging of the vessel (6). The objective of the present methodological study was to
demonstrate the usefulness of real-time three-dimensional transthoracic echocardiography
(RT3DE) for regional assessment of aortic stiffness. For this aim we demonstrate a case in
which the aortic arch was evaluated with RT3DE. To our knowledge this has not been
described before.
Methods
RT3DE was performed with a Philips Sonos 7500 ultrasound system (Philips, Best, The
Netherlands) attached to an X4 matrix array tranducer equipped with a 3D data acquisition
software package. The 3D data sets acquired from the supraclavicular window were analysed
off-line with assistance of the TomTec 4D Echo-View 5.3 workstation (TomTec Inc.,
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Unterschleissheim, Germany). The aortic lumen can be divided into several segments allowing
regional measurements of aortic stiffness. Several indices are used to describe and quantify the
physical behaviour of vessels in response to an intraluminal force. For the evaluation of aortic
stiffness index �, the following formula is used: �������������������������������������������
systolic and diastolic blood pressures, DD is the ao����������������������������������� ���������
minus diastolic aortic diameter and ’ln’ is the natural logarythm. For this elasticity parameter,
������������������ ��������������������������
According to this methodology, we evaluated aortic stiffness with RT3DE in a 24 year-
old healthy man. From the supraclavicular window, the aortic arch, the distal part of the
ascending aorta and the proximal part of the descending aorta were visualized. As seen in
Figure 1, the cut planes from the 3D data sets that visualized the aorta “en-face” could be
easily reconstructed. The reconstructed images allowed the segmental evaluation of aortic
cross-sections at different levels. Regional � values were calculated using the blood pressure
data (122/80 mm Hg) and regional aortic systolic and diastolic diameters.
Figure 1 a/b. Regional evaluation of aortic arch stiffness. By division of the aortic arch by
coaxial planes into 2 segments with RT3DE. Regional aortic stiffness indices (�) could be
calculated in each segment.
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Discussion
Aortic stiffness is an important predictor of cardiovascular morbidity and mortality (1). Non-
invasive measurement of aortic stiffness is a promising challenge for echocardiography. In
previous studies, it has been demonstrated that aortic stiffness can be measured during TTE
and TEE examinations (2-5). The most important limitation of these studies was that regional
differences for aortic stiffness were not taken into consideration. Regional stiffness of the
descending aorta can be characterized by 3D-TEE using horizontal aortic cross-sectional
images (6). In our patient, we demonstrated the usefulness of RT3DE in assessment of regional
aortic stiffness. However, it should be noted that the echocardiographic window quality (which
is somewhat lower compared to two-dimensional TTE) is still a limitation for 3D imaging in
some patients. Theoretically, as evidenced in ventricular quantification and carotid artery
studies, use of an echo contrast agent may improve aortic image quality (7,8).
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Summary and conclusions
The aim of this thesis was to study the advances in the evaluation of cardiovascular function by
2D and real-time 3D stress echocardiography and vascular stiffness measurements.
Stress echocardiography is a widely used non-invasive stress modality for the detection of
coronary artery disease The Part A of the thesis is focusing on this method demonstrating the
current status of 2D and real-time 3D echocardiography (RT3DE).
Chapter 2. Our review describes factors affecting sensitivity and specificity during
dobutamine stress echocardiography. This analysis suggests that the reported sensitivity of
dobutamine stress echocardiography is higher and the specificity lower than expected in
clinical practice. The reason can be the inappropriate inclusion of patients with prior
myocardial infarction, definition of positive DSE and the presence of referral bias.
From pooled data, Chapter 3 demonstrates that dobutamine stress echocardiography
carries a definite, albeit small, risk. Life-threatening complications occurred in approximately
one out of 400 patients. Before a stress stress is ordered, this risk should always be carefully
weighted against the expected diagnostic or prognostic benefit.
The use of ultrasound contrast can have a role in the improvement of image quality.
Because of safety concerns we systematically reviewed a consecutive series of patients all
adverse effects of SonoVue® in our echocardiographic laboratory. The reported incidence of
adverse effects of SonoVue® echo contrast in our small initial serie of cardiac patients seems
higher than those reported in a company post-marketing analysis and await confirmation
(Chapter 4).
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Chapter 5 provides an overview of the current status of stress RT3DE emphasizing its
advantages over stress 2D echocardiography but showing its current technical limitations.
RT3DE is easy to learn and a less time consuming imaging modality, which sees the left
ventricle (LV) as it truly is. With stress RT3DE, at each stress level only one 3D data
acquisition from one window is needed, which makes a 3D examination faster than
conventional 2D stress imaging. Another advantage can be, that from the acquired 3D
volumetric data sets, matching views at baseline and at different levels of stress can be
reconstructed for a precise comparison of identical segments. RT3DE even allows the anyplane
evaluation of LV helping to create short-axis views at different LV levels that may be easier to
understand by other (non-cardiologists) physicians. RT3DE thus offers several advantages over
2D echocardiography in the evaluation of LV function. Future studies in real-clinical practice
will show the clinical value of RT3DE over 2D echocardiography. In our opinion this imaging
modality is currently still hampered by some major technical limitations. Multibeat frame
composition, limited spatial resolution and large footprint of the special matrix-array
transducer actually form the major technical limitations. However, most of these limitations
may be overcome in the near future. With the development of more advanced automated
border detection software, we can expect a decrease in inter-observer variability associated
with visual scoring of segmental wall motion. Reduction of transducer footprint size will
further reduce rib shadowing. If 3D image quality can be brought to a comparable level as 2D
image quality, stress RT3DE may be more suitable for such automated analysis than stress 2D
echo because 3D images offer higher information content with complete LV visualization.
Provided that all these technical improvements will occur stress RT3DE may become an
important diagnostic test of the future.
Using recently available RT3DE equipment, our results demonstrate that a relatively
high number of myocardial segments are not adequately visualized with conventional stress
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RT3DE (146 of the 612 segments, 24%), but contrast-enhancement significantly decreases the
number of non-available myocardial segments (59 of the 612 segments, 10%) and improves
interobserver agreement for diagnosis of myocardial ischemia (study agreement from 72% to
89%) (Chapter 6).
Moreover, it has been demonstrated that addition of parasternal to apical acquisition of
contrast RT3DE data decreases the number of non-visualised segments (from 9% to 4%) and
improves mean image quality (from 2.43 to 2.74, p <0.05) (Chapter 7).
Finally, our case report demonstrates that cropped long- and short-axis images of LV
during contrast-enhanced stress RT3DE are comparable to magnetic resonance images, which
is a so-called `gold standard` for LV function imaging (Chapter 8).
Part B of the thesis is focusing on the evaluation of aortic stiffness in special patients
populations.
Aortic stiffness has been shown as a major contributory factor to cardiovascular morbidity and
mortality. M-mode echocardiography in combination with non-invasive blood pressure
measurements offers an opportunity to characterize vascular stiffness by calculating different
stiffness indices. Interestingly, despite the widely available literature with this method there is
little experience with storage diseases as glycogenosis type II (Pompe’s disease) (Chapter 9)
and mucopolysaccharidosis type I (Chapter 10). These disorders are associated with enzyme
deficiencies resulting in accumulation of deposits in different tissues. Our studies suggested
that aortic stiffness is increased in these storage diseases before morphological alterations can
be found. However, further follow-up studies are needed to examine arterial elasticity using
more reliable methods (RT3DE, magnetic resonance imaging or invasive measurements etc.).
Future enzymatic therapies may be followed on the effect of vascular distensibility by the
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methods described in the present thesis. Moreover, studies of stiffened aorta on coronary
perfusion in these patient populations are also warranted.
In recent studies increased aortic stiffness has been demonstrated in valvular aortic
stenosis (AS) as an early manifestation of the atherosclerotic process (endothelial dysfunction),
decreased perfusion of the aorta or other factors beyond physical pressure effects. However,
the long-term effect of aortic valve replacement on aortic elasticity has never been assessed.
The present study found a continuous improvement in aortic distensibility during a 1-year
follow-up after surgery. One of the possible explanations for improvement in vascular
elasticity may be recovery of damaged aortic root endothelium, which has an important role in
the production of vasorelaxant factors and pressure changes in the proximal aorta. However,
further long-term follow-up studies are required using other methods confirming our findings
mainly evaluating the different kinds of valve types and their effect on flow profile and aortic
distensibility (Chapter 11).
One of the main limitations of these studies is that regional differences in aortic
stiffness at segments of the aortic wall are not taken into consideration. Our report
demonstrates that RT3DE offers a special aspect on evaluation of regional aortic stiffness.
Further studies are warranted in large patient population in comparison with invasive direct
measurements for the evaluation of regional aortic stiffness (Chapter 12).
Conclusions. Recent advances in ultrasound technology have shown its advantages in clinical
cardiology such as real-time 3D echocardiography and vascular stiffness assessment. Despite
current technological limitations as has been described, these new technologies have provided
insight into understanding of cardiac and vascular pathophysiology. Limitations of RT3DE are
transducer footprint size, frame rate at higher heart rates and image quality. Future
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improvements in transducer technology such as harmonic 3D imaging, smaller transducers and
the use of different transducer materials are already tested for their usefulness in clinical
practice. Also newer algorhytms for automatic border detection will decrease current
subjectivity of analysis. For evaluation of aortic stiffness more reliable methods like real-time
3D echocardiography or MRI are under development allowing the exact evaluation not only
vascular diameter but shape changes during a heart cycle.

Samenvatting en conclusies
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Samenvatting en conclusies
Het doel van dit proefschrift is om nieuwe ontwikkelingen te laten zien in de evaluatie van de
cardiovasculaire functie en bepalingen van de stijfheid van de grote vaten gebruikmakend van
2D en 3D echocardiografie.
Stress-echocardiografie en met name Dobutamine Stress-Echo (DSE) is een veel voorkomende
algemeen gebruikte niet invasieve belastingtest voor de diagnostiek van coronaire hartziekte.
Het gedeelte A richt zich op de methodiek van 2D en real-time 3D echo in zijn huidige vorm.
Hoofdstuk 2. Dit overzichtsstuk beschrijft de factoren die sensitiviteit en specificiteit
beïnvloeden tijdens DSE. Onze analyse toont aan dat sensitiviteit van DSE hoger en de
specificiteit lager is dan verwacht. Een van de redenen is een waarschijnlijk onjuiste inclusie
van patiënten met een oud infarct, definitie van DSE en effect van klinische verwijzingen.
In hoofdstuk 3 tonen we aan dat DSE toch een risico, hoewel klein, geeft op
levensbedreigende complicaties. Dit wordt geschat op 1:400 onderzoeken. Dus late te
verwachten complicaties moeten afgewogen worden tegen de te verwachten diagnostische
informatie.
Het gebruik van ultrasound contrastmiddelen speelt ook een belangrijke rol voor de
verbetering van de beeldkwaliteit. Omdat er problemen met veiligheid van deze methode zijn
beschreven, hebben wij systematisch een aantal patiënten bestudeerd en gekeken naar de
ongewenste effecten van SonoVue. De incidentie van bijwerkingen in deze kleine serie van
patiënten met hartafwijkingen zijn hoger dan die gerapporteerd in een analyse nadat het middel
geregistreerd is en uitgevoerd door het bedrijf dat dit middel produceert (hoofdstuk 4).
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Hoofdstuk 5 geeft een overzicht van de huidige status van stress real-time 3D echo en
benadrukt de voordelen boven stress 2D echo, maar toont ook de huidige technische limitaties
van de techniek. Real-time 3D echo is makkelijk te leren en minder tijdrovend dan de huidige
technieken. Met behulp van stress real-time 3D is op elk niveau van de stress alleen een 3D
data set nodig van één echo window. Dit maakt een 3D onderzoek sneller dan het
conventionele 3D stress onderzoek. Een ander voordeel is dat van de opgenomen 3D
volumetrische datasets exact dezelfde doorsneden, zowel in rust als van de verschillende
niveaus van stress kunnen worden gereconstrueerd. Dat maakt een precieze vergelijking van
identieke segmenten mogelijk. Real-time 3D kan ook andere doorsneden construeren van
bijvoorbeeld de korte as op verschillende niveaus van de linker kamer. Real-time 3D geeft dus
verschillende voordelen boven 2D echo in de evaluatie van de linker kamerfunctie.
Toekomstige studies met deze techniek in de echte klinische praktijk zullen de klinische
waarde van de real-time 3D boven 2D echo laten zien. Wij zijn van mening dat deze
beeldvormende techniek toch nog behoorlijke technische beperkingen kent. Er is een veelheid
van opnamebeelden nodig om een beeld te construeren. Er is beperkte resolutie ten gevolge
van de grootte van de transducer. De meeste van deze beperkingen zullen in de toekomst
worden overwonnen. Met de ontwikkeling van geavanceerde automatische detectie van
endocardiale grensvlakken kunnen wij een verlaging verwachten van de interobserver
variabiliteit. Een kleinere transducer zal verdere schaduwbeelden verminderen. Als de 3D
beeldkwaliteit vergelijkbaar wordt met de huidige 2D beeldkwaliteit zal stress real-time 3D
meer bruikbaar zijn voor automatische analyse dan 2D omdat stress 3D een meer compleet
beeld van de linker kamer geeft. Als al deze technische beperkingen worden opgelost zal stress
real-time 3D echo een belangrijke diagnostische test in de toekomst worden.
Gebruikmakend van nieuwe real-time 3D technologie toont dat een hoog aantal
myocardiale segmenten niet kunnen worden zichtbaar gemaakt met conventionele real-time 3D
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echo (146 van 612 segmenten, 24%). Echter, het gebruik van ultrasound contrast toont een
forse afname van de niet zichtbare segmenten (59 van 612 segmenten, 10%). Het verbetert dus
de interobserver variabiliteit. Voor diagnose van myocard ischemie stijgt de overeenstemming
tussen 2 observers van 72% naar 89% (hoofdstuk 6).
Indien aan de apicale acquisitie ook de parasternale acquisitie wordt toegevoegd met
behulp van contrast real-time 3D echo, daalt het aantal niet zichtbare segmenten duidelijk van
9% tot 4% en neemt de beeldkwaliteit toe (van 2.43 tot 2.74 p <0.05) (hoofdstuk 7).
Tenslotte, dit laatste klinische voorbeeld laat zien dat lange as en korte as beelden van
de linker kamer gedurende stress real-time 3D met behulp van contrastmiddelen een
vergelijkbare kwaliteit hebben als dezelfde beelden gemaakt bij de patiënt indien gebruik
gemaakt wordt van MRI, wat de gouden standaard voor deze linker kamer beeldvormende
techniek is (hoofdstuk 8).
Het gedeelte B van dit proefschrift richt zich op de evaluatie van de stijfheid van de aorta in
speciale patienten groepen.
Stijfheid van de aorta is een belangrijke factor die bijdraagt aan cardiovasculaire functie
kwaliteit en morbiditeit. M-mode echo in combinatie met niet invasieve bloeddrukmeting
vormt een mogelijkheid om de vasculaire stijfheid te bepalen. Hoewel deze techniek vrij veel
wordt gebruikt is in de literatuur weinig te vinden over de toepassing bij stapelingsziekten
zoals ziekte van Pompe (hoofdstuk 9) en mucopolysaccharidosis (hoofdstuk 10). Deze ziektes
zijn geassocieerd met enzymafwijkingen resulterend in accumulatie van neerslagen in de
verschillende weefsels. Onze studie laat zien dat de aortastijfheid toegenomen is bij deze
stapelingsziekte voordat er morfologische veranderingen worden gevonden. Echter, verdere
follow-up studies zijn nodig om onze bevindingen te bevestigen, eventueel gebruikmakend van
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realtime 3D en MRI. In de toekomst zullen mogelijk enzymatische therapieën beschikbaar
worden waarbij deze methode gebruikt kan worden voor de follow-up van deze patiënten.
Verder zijn deze studies nodig naar de stijfheid van de aorta op het effect van de coronaire
perfusie in deze patiënten.
In recente publicaties is ook toename van de aortastijfheid beschreven bij valvulaire
aortastenose als een vroege manifestatie van aortasclerose, verminderde perfusie van de aorta
of andere factoren buiten de bekende factoren die reeds bekend zijn. Echter, de lange termijn
effecten van aortaklep vervanging op aorta stijfheid en elasticiteit zijn nooit beschreven. De
huidige studie toont een verbetering in de aorta elasticiteit aan gedurende een follow-up van 1
jaar na chirurgie. Een van de verklaringen zou kunnen zijn dat de beschadigde aorta wortel
weer wordt hersteld zodat een verbeterd aorta wortel endotheel vaso relaxatie factoren kunnen
produceren. Echter, lange termijn studies in deze patiënten is nodig om onze resultaten te
bevestigen (hoofdstuk 11).
Een van de voornaamste beperkingen van deze studies is dat regionale veranderingen in
de aortastijfheid niet in overweging worden genomen. Onze studie laat zien dat realtime 3D
een speciaal effect van de evaluatie van de regionale aorta stijfheid laat zien. Verdere studies in
grotere patiënten populaties met invasieve directe metingen zijn nodig om deze regionale
stijfheid te bepalen (hoofdstuk 12).
Conclusies. Huidige verbeteringen in de ultrasound technologie hebben laten zien dat
diagnostische verbeteringen in de klinische cardiologie zoals real-time 3D echo en
stijfheidbepaling van de vaten kunnen plaatsvinden. Hoewel er nog technologische
beperkingen zijn, geven deze nieuwe technologieën toch inzage in de pathofysiologie van hart
en bloedvaten. Beperkingen van real-time 3D zijn de grootte van de transducer, het aantal
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beelden per seconde dat voornamelijk een beperking is bij hogere hartslagen en beeldkwaliteit.
Toekomstige verbeteringen in transducer technologie, zoals harmonische 3D beeldvorming,
kleinere transducers en andere transducer materialen zijn al in het stadium van technische
evaluatie. Ook nieuwe algoritmes voor betere automatische detectie van endocardiale vlakken
zullen nodig zijn. Voor evaluatie van de stijfheid van de aorta zullen meer betrouwbare
methodes zoals 3D of MRI ontwikkeld moeten worden om niet alleen de vasculaire diameter
maar ook de vorm van de vaten gedurende de hartcyclus te bepalen.
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